Bivalent nucleic acid ligand and use therefor

Bivalent nucleic acid ligands targeting expanded RNA repeats in Huntington's disease and other polyQ diseases address the multivariate disorder by reducing RNA toxicity, providing a therapeutic approach to ameliorate symptoms.

JP2024161489AActive Publication Date: 2024-11-19CARNEGIE MELLON UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024135571
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-02-14
Filing Date
2024-08-15
Publication Date
2024-11-19
Estimated Expiration
2038-12-21

AI Technical Summary

Technical Problem

Current treatments for Huntington's disease and other polyQ diseases do not fully address the multivariate disorder caused by toxic acquisition of RNA and protein function, as they primarily focus on protein function loss or gain, neglecting the role of expanded RNA transcripts.

Method used

Development of bivalent nucleic acid ligands that selectively target expanded RNA repeats, such as CAG repeats, to interfere with multiple disease pathways by binding to nucleic acid strands and modulating gene expression.

Benefits of technology

The bivalent nucleic acid ligands effectively reduce the expression of expanded RNA repeats, leading to clinically significant inhibition of mRNA and amelioration of symptoms in polyQ diseases like Huntington's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161489000001_ABST
    Figure 2024161489000001_ABST
Patent Text Reader

Abstract

To provide one promising strategy for treating a HD, the HD being a multivariate disorder caused by toxic acquisition of RNA and protein function, is to selectively target an expanded transcript because this interferes with all three disease pathways; and to use a bivalent nucleic acid ligand for recognition of rCAG repeat and other RNA-repeat sequences.SOLUTION: Genetic recognition reagents comprising bivalent nucleobases are provided that bind two strands of nucleic acid, such as an expanded repeat sequence associated with an expanded repeat disease. In one example, the expanded repeat disease is a polyQ disease, such as Huntington's disease. Methods of use of the reagents, including a method of binding nucleic acid, such as an expanded repeat sequence associated with an expanded repeat disease, a method of identifying the presence of nucleic acid comprising an expanded repeat, and a method of treating an expanded repeat disease, are provided.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Federal Grant Complaints This invention was made with government support under Grant No. R21NS098102 awarded by the National Institutes of Health and Grant No. CHE1039870 awarded by the National Science Foundation. The government has certain rights in the invention.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of co-pending U.S. Provisional Patent Application No. 62 / 708,783, filed December 21, 2017, and U.S. Provisional Patent Application No. 62 / 710,262, filed February 14, 2018, each of which is incorporated herein by reference in its entirety.

[0003] The sequence listing associated with this application has been submitted in electronic format via EFS-Web and is incorporated herein by reference in its entirety. The name of the text file containing the sequence listing is 6526_1807597_ST25.txt. The size of the text file is 444 bytes and the text file was created on December 21, 2018.

[0004] 1. Field of the invention Described herein are compositions for binding nucleic acids using nucleic acid and nucleic acid oligomer compositions. Also provided are methods for treating expanded repeat diseases, e.g., PolyQ diseases, such as Huntington's disease. [Background technology]

[0005] 2. Description of Related Art RNA-repeated expansions are common in neuromuscular disorders (or diseases). One example is Huntington's disease (HD), an autosomal dominant disorder that affects muscle coordination and leads to behavioral changes, cognitive decline, and dementia. HD typically develops in middle age and results in death 10-20 years after onset. It is caused by the expansion of CAG repeats in the first exon of the Huntington (htt) gene from the normal range of 6-29 to the pathogenic range of 40-180. exp The length of the Htt repeat is inversely proportional to the age of onset. Htt is expressed ubiquitously, but mainly in neurons of the CNS, and encodes a 348 kDa protein with diverse physiological roles, including embryonic development and neuroprotection. CAG repeats are translated into polyglutamine (polyQ) sequences in the N-terminal region of Htt. Despite the vast information on molecular dysfunction and clinical manifestations, the CAG repeats are not well understood. exp The precise mechanisms that cause HD are still not fully understood, however, emerging evidence suggests that HD is a multivariate disorder.

[0006] Loss of protein function may contribute to the pathogenesis of HD, but CAG expHeterozygous and homozygous patients with htt have similar clinical features, making it unlikely to be the primary cause. Furthermore, individuals have been identified that have a 50% reduction in normal Htt protein levels due to deletion of one of the htt alleles, yet do not display any abnormal phenotype. Similarly, mice heterozygous for htt null mutations do not display clinical features of HD, and homozygotes die during early embryonic development. These findings highlight the importance of Htt in embryonic development, but not in the pathogenesis of HD. Emerging evidence points to a deleterious gain of function as a more plausible cause of the disease. This suggestion is supported by the observation that CAG repeats above a similar threshold (30–40 units) in unrelated genes are responsible for several neuromuscular disorders in addition to HD, including DRPLA (dentatorubral-pallidoluysian atrophy), SBMA (spinal-bulbar muscular atrophy), SCA1 (spinocerebellar ataxia type 1), SCA2 (spinocerebellar ataxia type 2), SCA3 (spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (spinocerebellar ataxia type 6), SCA7 (spinocerebellar ataxia type 7), and SCA17 (spinocerebellar ataxia type 17). These disorders, termed polyQ diseases, share many hallmarks with HD, including subcortical and cortical atrophy, as well as nuclear aggregates.

[0007] Three main cytotoxic mechanisms have been proposed for HD and other polyQ-diseases. The first is polyQ toxicity. PolyQ has a tendency to aggregate and interact with other polyQ-containing proteins to form large amyloid-like structures. Binding and sequestration of these key proteins leads to the loss of their physiological functions, resulting in the dysregulation of a cascade of molecular and cellular events. The second is toxic-gain of RNA function. Upon transcription, rCAG exp The rCAG repeat adopts an imperfect hairpin structure that sequesters muscleblind-like protein 1 (MBNLl), an alternative RNA splicing regulator, and other key proteins. Normal rCAG repeats can also adopt hairpin motifs, but in a different sequence context than the expanded version. rCAGexp Association of MBNL1 with MBNL1 results in a complex trapped in the nucleus as nuclear foci and unable to be transported to the cytoplasm for production of Htt protein. Loss of MBNL1 results in a variety of misspliced ​​gene transcripts. A third pathogenic mechanism is proteotoxicity. It has been shown that rCAG repeats beyond a certain length (>42 units) are translated via repeat-associated non-ATG (RAN) translation in the absence of an ATG start codon, leading to the production of toxic polyQ and polyalanine (polyA) proteins together with polyserine (polyS). The latter two mechanisms are further supported by the finding that expression of long untranslated rCAG repeats is deleterious in animal models, with abnormal behavioral phenotypes similar to those of HD. Summary of the Invention [Problem to be solved by the invention]

[0008] Overall, these findings indicate that HD is a multivariate disorder caused by toxic gain of RNA and protein function.Therefore, one promising strategy for treating HD is to selectively target the expanded transcript, since this interferes with all three disease pathways.Described herein are bivalent nucleic acid ligands for the recognition of rCAG repeats and other RNA-repeat sequences. [Means for solving the problem]

[0009] Summary of the Invention In one embodiment, a gene recognition reagent is provided, the reagent comprising a nucleic acid or nucleic acid analog backbone comprising three or more ribose, deoxyribose, or nucleic acid analog backbone residues, and a bivalent nucleobase sequence bound to the backbone residues, wherein the bivalent nucleobase sequence binds to a target sequence of an expanded repeat of a repeat expansion disease on two nucleic acid strands, or one or more sequential repeats of a target sequence. In another embodiment, a composition is provided comprising a gene recognition reagent and a pharma- ceutically acceptable carrier.

[0010] In another embodiment, a method for binding a nucleic acid containing an expanded repeat associated with a repeat expansion disease is also provided, comprising contacting the nucleic acid containing the expanded repeat with a gene recognition reagent comprising a nucleic acid or nucleic acid analog backbone comprising three or more ribose, deoxyribose, or nucleic acid analog backbone residues, a bivalent nucleobase sequence bound to the backbone residues, wherein the bivalent nucleobase sequence binds to the amplicon target sequence of the expanded repeat of the repeat expansion disease on two nucleic acid strands, or one or more sequential repeats of the amplicon target sequence.

[0011] In yet another embodiment, a method is provided for identifying the presence of a nucleic acid comprising an expanded repeat associated with a repeat expansion disease in a sample obtained from a patient. The method includes contacting a nucleic acid sample obtained from the patient with a genetic recognition reagent comprising a nucleic acid or nucleic acid analog backbone comprising three or more ribose, deoxyribose, or nucleic acid analog backbone residues, a bivalent nucleobase sequence attached to the backbone residues, wherein the bivalent nucleobase sequence binds to a target unit sequence of an expanded repeat of a repeat expansion disease on two nucleic acid strands, or one or more sequential repeats of a target unit sequence, determining whether binding and ligation of the genetic recognition reagent occurs as an indication that the sample contains a nucleic acid comprising an expanded repeat associated with a repeat expansion disease, and optionally treating the patient for the repeat expansion disease. The nucleic acid or nucleic acid analog backbone comprises a first end and a second end, and further comprises a first linking group attached to the first end of the backbone, and a second linking group attached to the second end that non-covalently binds or self-ligates to the first linking group.

[0012] In yet another embodiment, a method is provided for knocking down expression of a gene containing an expanded repeat associated with a repeat expansion disease in a cell, the method comprising contacting a nucleic acid, such as an RNA, containing the expanded repeat with a gene recognition reagent comprising a nucleic acid or nucleic acid analog backbone comprising three or more ribose, deoxyribose, or nucleic acid analog backbone residues, a bivalent nucleobase sequence bound to the backbone residues, wherein the bivalent nucleobase sequence binds to a target sequence of the expanded repeat of the repeat expansion disease on two nucleic acid strands, or one or more sequential repeats of the target sequence. [Brief description of the drawings]

[0013] [Figure 1]Figure 1 (A) (Figure 1, panel (A)) Design of JB-MPγPNA ligands LG1, LG2, and LG3 to target the rCAGexp-hairpin structure; K: L-lysine; arrow: N-terminus; (B) Representative binding mode of LG2 in the preferred antiparallel orientation (N-terminus facing the 3' end of the Watson strand); (C) H-bond interactions of E, I, and F with CG, AA, and GC base pairs of RNA, respectively; (D) Chemical structure of MPγPNA backbone with covalently attached J bases; (E) Assumption of γPNA and γPNA-DNA duplexes and PNA [PNA-DNA duplexes] confirmed by NMR and X-ray. [Diagram 2] FIG. 2, panels A-F show exemplary structures of nucleic acid analogs. [Diagram 3] FIG. 3 shows various examples of amino acid side chains. [Figure 4] FIG. 4 shows exemplary nucleobase structures. [Figure 5A] 5A-5C show exemplary divalent nucleobase structures, where R refers to a nucleotide or nucleotide analog backbone monomer or residue. [Figure 5B] 5A-5C show exemplary divalent nucleobase structures, where R refers to a nucleotide or nucleotide analog backbone monomer or residue. [Figure 5C] 5A-5C show exemplary divalent nucleobase structures, where R refers to a nucleotide or nucleotide analog backbone monomer or residue. [Figure 6]MD simulation results of LG1 binding to an RNA duplex containing the sequence r(CAG)4 / r(CAG)4. LG1:NH2-EIF-H, γ side chain is a methyl group. (A) Surface representation of the binding complex of four separate LG1 ligands with an RNA duplex containing four CAG repeats before (t=0) and after (t=100ns) simulation. (B) H-bond interactions of CEG, AJA, and GFC triads after simulation. (C) Number of H-bonds per triad between RNA bases and J bases of LG1, (D) radius of gyration of LG I-RNA complex, and (E) root mean square deviation (RMSD) of LG I-RNA complex with respect to the initial structure. [Figure 7] FIG. 7 shows the structures of the E, I, and F JB-MPγPNA monomers. [Figure 8] 8 and 9 show the synthetic schemes for E(15) and F(26), respectively. [Figure 9] 8 and 9 show the synthetic schemes for E(15) and F(26), respectively. [Figure 10] FIG. 10 shows a scheme for coupling of E(15), F(26), and I(27) to the MPγPNA backbone. [Figure 11] FIG. 11 shows the model RNA target selected for binding studies described in the Examples (SEQ ID NO:1). [Figure 12] Figure 12 is a CD titration of LG2 with R11A. The concentration of R11A was 0.5 μM and the concentrations of LG2 were: X: 0, 1.5, 2.5, 3.5, 4.5, 5.5, 6.5, 8.5, and 11.5 μM. After addition of LG2 to R11A, the mixture was incubated at 37°C for 30 min, and then data was acquired at 25°C. [Figure 13] Figure 13 shows the CD spectra of LG2 with (A) the mismatched R11U, (B) the single-stranded WS and CS, and (C) the double-stranded HP containing a single binding site, and (D) the CD spectra of LG2P with R11A, the CD spectrum of RNA (solid line), and the CD spectrum of the [RNA + ligand] mixture (dashed line). [Figure 14]Figure 14: Effect of ligand orientation (LG2P), mismatch R11U and single-stranded target (WS+CS). Inset is the fluorescence spectrum of the corresponding sample after addition of 2.5 μM pentamidine. [Figure 15] Figure 15 is an NMR titration of LG2 with R11A. The concentration of R11A was 0.1 mM. Aliquots of LG2 at the indicated molar ratios were added to R11A and incubated for 15 minutes at 37°C prior to data collection. Solvent exchangeable protons are shown as dashed lines and non-exchangeable protons are shown as solid vertical lines. [Figure 16] FIG. 16 shows a schematic of native chemical ligation, as described in the Examples. [Figure 17] Figure 17: Reaction progress of the parent compound M after the addition of 4MP at 37°C. (A) Schematic of the reaction sequence. M# and M## intermediates were first formed, then converted to the reactive LG2N* intermediate, and finally to the cyclic product cLG2N. (B) MALDI-TOF MS spectra of M after the addition of 4MP and incubation at 37°C for 0, 15, and 60 minutes. The samples were prepared in 0.1x PBS buffer. [Figure 18] Figure 18 shows MALDI-TOF spectra of (A) [LG2N+R11A], (B) [LG2N+R11U], and (C) LG2N alone after incubation with 2ME for 16 hours at 37°C. Prior to MS analysis, the samples were renatured with 4 mM guanidinium chloride and heat denatured at 95°C for 5 minutes. The concentrations of LG2N, R11A, R11U, and 2ME were 22, 1, 1, and 500 μM, respectively. In the positive mode, no RNA molecules were observed in the MALDI-TOF spectra. The Y-axis in (B) and (C) is the same as that in (A) and has been omitted to save space. [Figure 19]Figure 19 is a competitive binding assay. The concentrations of R24A, R127A, and R96U were 100, 18, and 22 nM, respectively, each containing 1.1 μM of binding sites, the concentrations of LG2N in lanes 2-6 and 8 were 11, 22, 44, 88, 88, and 88 μM, respectively, and the concentrations of 4MP and TCEP were 500 and 100 μM, respectively. The ratio of binding sites to ligand was as indicated. The samples were prepared in 0.1×PBS buffer and incubated at 37° C. for 24 hours, then separated on a 2% agarose gel and stained with SYBR-Gold. [Figure 20] Figure 20: Gel shift assay at physiologically simulated ionic strength. Samples were prepared in the same manner as shown in Figure 9, except that the buffer was PS (10 mM NaPi, 150 mM KCl, 2 mM MgCl2 pH 7.4). The concentrations of R24A, R127A, and R96U were 100, 18, and 22 nM, respectively, each containing 1.1 μM of binding sites, the concentrations of LG2N in lanes 2-6 and 8 were 11, 22, 44, 88, 88, and 88 μM, respectively, and the concentrations of 4MP and TCEP were 500 and 100 μM, respectively. The ratios of binding sites to ligand were as indicated. The samples were incubated at 37°C for 24 hours, then separated on a 2% agarose gel and stained with SYBR-Gold. [Figure 21] FIG. 21 shows a general method for synthesizing the ligands described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description of the Invention The use of numerical values ​​in the various ranges specified in this application, unless otherwise indicated, is indicated as an approximation, as if the word "about" was placed before both the minimum and maximum values ​​in the stated range. In this manner, small variations above and below the stated ranges can be used to achieve substantially the same results as values ​​within the range. Also, unless otherwise indicated, the disclosure of ranges is intended as a continuous range including all values ​​between the minimum and maximum values. As used herein, the singular forms "a" and "an" refer to one or more.

[0015] As used herein, the term "comprising" is open-ended and may be synonymous with "including," "containing," or "characterized by." The term "consisting essentially of" limits the claim to the specified materials or steps and to materials or steps that do not materially affect one or more of the basic and novel characteristics of the claimed invention. The term "consisting of" excludes any element, step, or ingredient not specified in the claim. As used herein, embodiments that "comprising" one or more elements or steps also include, but are not limited to, embodiments that "consist essentially of" and "consist of" those specified elements or steps.

[0016] Provided herein are compositions and methods for binding target sequences in nucleic acids, for example, binding repeat expansions associated with diseases involving repeat expansions in nucleic acid sequences. Figure 1 is a schematic diagram showing the binding of non-limiting examples of the recognition reagents (genetic recognition reagents, ligands) described herein that target CAG repeats in RNA hairpin structures as seen in HD and other PolyQ diseases. Cooperative binding of modules to adjacent modules is promoted by terminal self-ligating groups or π-stacking aromatic groups, such as the exemplary self-ligating groups described in the following examples and more broadly disclosed in US Patent Publication No. 2016 / 0083433, which is incorporated herein by reference. In summary, self-ligating groups, π-stacking groups, and similar groups that covalently or non-covalently link adjacent recognition reagents between two nucleic acid strands on a strand of nucleic acid or in a recognition reagent that comprises a divalent nucleic acid base are collectively referred to herein as "linking groups". The multiple recognition reagents bind (hybridize) to the template nucleic acid by Watson-Crick or Watson-Crick-like cooperative base pairing. In a cell, the template nucleic acid is an RNA or DNA molecule, but in vitro, the template nucleic acid can be any RNA or DNA, as well as modified nucleic acids or nucleic acid analogs. Recognition reagents that bind to sufficiently close, e.g., adjacent sequences on the template nucleic acid, self-ligate or π-π stack, thus linking to essentially form a longer oligomer or polymer. Further details are provided below.

[0017] As used herein, a "patient" is an animal, such as a mammal, including a primate (e.g., a human, a non-human primate, such as a monkey, and a chimpanzee), a non-primate (e.g., a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, a horse, and a whale), or a bird (e.g., a duck or a goose).

[0018] As used herein, the term "treat" or "treatment" refers to a beneficial or desired result, such as ameliorating one or more symptoms of a disease. The term "treat" or "treatment" also includes, but is not limited to, reducing or ameliorating one or more symptoms of a repeat expansion disease, such as a PolyQ repeat expansion disease, e.g., Huntington's disease. "Treatment" can also mean prolonging survival compared to expected survival in the absence of treatment.

[0019] "Lower" in the context of disease markers or symptoms means a clinically relevant and / or statistically significant decrease in such levels. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40% or more, to a level that is accepted as being within the normal range for individuals without such disorders, or to a level below the detection level of the assay. In certain embodiments, the decrease can also be referred to as normalization of levels, a decrease to a level that is accepted as being within the normal range for individuals without such disorders. In certain embodiments, the decrease is a normalization of the level of a disease sign or symptom, a decrease in the difference between the subject level of the disease sign and the normal level of the sign for the disease (e.g., to an upper level of normal if the level for the subject must be decreased to reach a normal value, and to a lower level of normal if the value for the subject must be increased to reach a normal level). In some embodiments, the methods include clinically meaningful inhibition of expression of mRNA for a polyQ repeat expansion disease, e.g., Huntington's disease, as demonstrated, for example, by a clinically meaningful outcome following treatment of a subject with a recognition reagent as described herein.

[0020] As used herein, a "therapeutically effective amount" is intended to include an amount of the recognition reagent described herein that is sufficient to effect treatment of the disease (e.g., by reducing, improving or maintaining an existing disease or one or more symptoms of the disease) when administered to a subject having a disease. The "therapeutically effective amount" may vary depending on the recognition reagent (drug), the method of administration of the drug, the disease and severity of the disease, as well as the medical history, age, weight, family history, genetic makeup, type of prior or concomitant treatment, if any, and other individual characteristics of the subject to be treated. In the context of the genetic recognition reagents described herein, an exemplary dosage range per dose is in the range of 0.1 pg to 1 mg.

[0021] A "therapeutically effective amount" also includes that amount of an agent that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. The recognition reagent agents used in the methods described herein may be administered in amounts sufficient to provide a reasonable benefit / risk ratio applicable to such treatment.

[0022] As used herein, the phrase "pharmaceutical acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium, calcium, or zinc stearate, or stearic acid), or solvent encapsulating material, that is involved in carrying or transporting a compound of interest from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject to be treated. Some examples of materials which can act as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and cellulose derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; and (7) lubricants, such as magnesium stearate. state), sodium lauryl sulfate and talc, (8) excipients, such as cocoa butter and suppository wax, (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil, (10) glycols, such as propylene glycol, (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol, (12) esters, such as ethyl oleate and ethyl laurate, (13) agar, (14) buffers. , such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) pH buffer solutions, (21) polyesters, polycarbonates and / or polyanhydrides, (22) bulking agents, such as polypeptides and amino acids, (23) serum components, such as serum albumin, HDL and LDL, and (22) other non-toxic compatible substances used in pharmaceutical formulations.

[0023] As used herein, the terms "cell" and "cells" refer to any type of cell from any animal, including, but not limited to, rat, mouse, monkey, and human. For example, but not limited to, the cells can be progenitor cells, such as stem cells, or differentiated cells, such as endothelial cells, smooth muscle cells, etc.

[0024] "Expression" or "gene expression" refers to the overall information flow from a gene for the production of a gene product (typically a protein, optionally post-translationally modified or functional / structural RNA) (including but not limited to a functional genetic unit for producing a gene product such as RNA or protein in a cell, or other expression system encoded on a nucleic acid and including a transcriptional promoter and other cis-acting elements, such as response elements and / or enhancers, an expressed sequence that typically encodes a protein (open reading frame or ORF) or functional / structural RNA, as well as a polyadenylation sequence). "Expression of a gene under the transcriptional control" of a specified sequence, or "controlled by" a specified sequence, refers to gene expression from a gene that includes the specified sequence operably linked (typically functionally linked in cis) to said gene. The specified sequence may be all or part of a transcriptional element (including but not limited to a promoter, enhancer and response element) and may regulate and / or affect the transcription of a gene in whole or in part. A "gene for expression" of a indicated gene product is a gene that is capable of expressing the indicated gene product when placed in an appropriate environment, i.e., when a cell is transformed, transfected, transduced, etc. and subjected to suitable conditions for expression. In the case of a constitutive promoter, "appropriate conditions" means that the gene typically only needs to be introduced into the host cell. In the case of an inducible promoter, "appropriate conditions" means when an effective amount of the respective inducer is administered to the expression system (e.g., cell) to cause expression of the gene.

[0025] As used herein, the term "knockdown" or "knock down" refers to the expression of one or more genes in an organism being reduced, typically significantly, for functional genes, such as to a therapeutically effective extent. Gene knockdown also includes complete gene silencing. As used herein, "gene silencing" refers to the expression of a gene being essentially completely prevented. Knockdown and gene silencing can occur at either the transcription or translation stage. The use of the described recognition reagents to target RNA in cells, such as mRNA, can modify gene expression by knocking down or silencing one or more genes at the post-transcription or translation stage.

[0026] As used herein, the term "nucleic acid" refers to deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Nucleic acid analogs include, for example, but are not limited to, 2'-O-methyl substituted RNA, locked nucleic acid, unlocked nucleic acid, triazole-linked DNA, peptide nucleic acid, morpholino oligomers, dideoxynucleotide oligomers, glycol nucleic acid, threose nucleic acid, and combinations thereof, optionally containing one or more ribonucleotide or deoxyribonucleotide residues. As used herein, "nucleic acid" and "oligonucleotide," which are short single-stranded structures composed of nucleotides, are used interchangeably with respect to nucleic acids and nucleic acid analogs. Oligonucleotides may be referred to by the length of the chain (i.e., the number of nucleotides) by the nomenclature "-mer." For example, an oligonucleotide of 22 nucleotides would be referred to as a 22-mer.

[0027] A "nucleic acid analog" is a composition that includes an array of nucleic acid bases arranged on a substrate, such as a polymer backbone, and can bind DNA and / or RNA by hybridization through Watson-Crick hydrogen bond base pairing or Watson-Crick-like hydrogen bond base pairing. Non-limiting examples of common nucleic acid analogs include peptide nucleic acids, such as gamma PNA, morpholino nucleic acids, phosphorothioates, locked nucleic acids (2'-O-4'-C-methylene bridges including oxy, thio or amino types), unlocked nucleic acids (C2'-C3' bonds are broken), 2'-O-methyl substituted RNA, threose nucleic acid, glycol nucleic acid, and the like.

[0028] A conformationally preorganized nucleic acid analog is a nucleic acid analog having a backbone (preorganized backbone) that forms only right-handed or left-handed helices depending on the structure of the nucleic acid backbone. As shown herein, an example of a conformationally preorganized nucleic acid analog is γPNA, which has a chiral center at the γ carbon and forms only right-handed or left-handed helices depending on and because of the chirality of the group at the γ carbon. Similarly, a locked nucleic acid includes a ribose with a bridge between the 2' oxygen and the 4' carbon that "locks" the ribose into a 3'-endo (north) conformation.

[0029] In the context of this disclosure, "nucleotide" refers to a monomer that includes at least one nucleobase and a backbone element, which in nucleic acids such as RNA or DNA is ribose or deoxyribose. "Nucleotide" also typically includes reactive groups that allow polymerization under certain conditions. In natural DNA and RNA, these reactive groups are 5' phosphate and 3' hydroxyl groups. For chemical synthesis of nucleic acids and nucleic acid analogs, the base and backbone monomers may include modified groups, such as blocked amines, as known in the art. "Nucleotide residue" refers to a single nucleotide that is incorporated into an oligonucleotide or polynucleotide. Similarly, "nucleobase residue" refers to a nucleobase that is incorporated into a nucleotide or nucleic acid or nucleic acid analog. "Genetic recognition reagent" refers generally to a nucleic acid or nucleic acid analog that includes a sequence of nucleobases that can hybridize (bind) to a complementary nucleic acid or nucleic acid analog sequence on a nucleic acid by cooperative base pairing, such as Watson-Crick base pairing or Watson-Crick-like base pairing.

[0030] More specifically, a nucleotide has the structure AB, for either RNA, DNA, or nucleic acid analogs, where A is the backbone monomer portion and B is the nucleic acid base as described herein. The backbone monomer can be any suitable nucleic acid backbone monomer, such as ribose triphosphate or deoxyribose triphosphate, or a monomer of a nucleic acid analog, such as a peptide nucleic acid (PNA), e.g., gamma PNA (γPNA). In one example, the backbone monomer is a ribose monophosphate, diphosphate, or triphosphate or a deoxyribose monophosphate, diphosphate, or triphosphate, e.g., the 5' monophosphate, diphosphate, or triphosphate of ribose or deoxyribose. The backbone monomer includes both the structural "residue" component, such as ribose in RNA, and any active groups that are modified when linking the monomers together, e.g., both the 5' triphosphate group and the 3' hydroxyl group of a ribonucleotide that are modified to leave a phosphodiester bond when polymerized into RNA. As in the case of PNA, the C-terminal carboxyl group and the N-terminal amine active group of the N-(2-aminoethyl)glycine backbone monomer condense during polymerization to leave a peptide (amide) bond. In another embodiment, the active group is a phosphoramidite group, which is useful for phosphoramidite oligomer synthesis, as is widely known in the art. The nucleotide also optionally includes one or more protecting groups as described herein, such as 4,4'-dimethoxytrityl (DMT), which are known in the art. Many additional methods are known for preparing synthetic gene recognition reagents, which depend on the specific chemical properties of the backbone structure and the base addition process. The decision of which active group to utilize for the attachment of nucleotide monomers, which groups to protect on the bases, and the steps required in the preparation of the oligomer are well within the capabilities of those skilled in the art of chemistry and nucleic acid and nucleic acid analog oligomer synthesis.

[0031] Non-limiting examples of common nucleic acid analogs include peptide nucleic acids, e.g., gamma PNA, phosphorothioates (e.g., FIG. 2(A)), locked nucleic acids (2'-O-4'-C-methylene bridges including oxy, thio or amino forms, e.g., FIG. 2(B)), unlocked nucleic acids (C2'-C3' bonds are cleaved, e.g., FIG. 2(C)), 2'-O-methyl substituted RNA, morpholino nucleic acids (e.g., FIG. 2(D)), threose nucleic acids (e.g., FIG. 2(E)), glycol nucleic acids (e.g., FIG. 2(F), showing R and S forms), etc. Figures 2(A-F) show monomer structures for various examples of nucleic acid analogs. Each of FIGS. 2(A-F) shows two monomer residues incorporated into a longer chain, shown by a wavy line. The incorporated monomer is referred to herein as a "residue" and the portion of the nucleic acid or nucleic acid analog excluding the nucleobase is referred to as the "backbone" of the nucleic acid or nucleic acid analog. As an example, in the case of RNA, an exemplary nucleobase is adenine, the corresponding monomer is adenosine triphosphate, and the incorporated residue is an adenosine monophosphate residue. In the case of RNA, the "backbone" consists of ribose subunits linked by phosphate, and thus the backbone monomer is a ribose triphosphate before incorporation and a ribose monophosphate residue after incorporation. Similar to γPNA, locked nucleic acids (FIG. 2(B)) are conformationally preorganized.

[0032] A "moiety" is a portion of a molecule, and as a class includes "residues," which are the portions of a compound or monomer that remain in a larger molecule, such as a polymer chain, following incorporation of the compound or monomer into the larger molecule, e.g., a nucleotide as incorporated into a nucleic acid, or an amino acid as incorporated into a polypeptide or protein.

[0033] The term "polymer composition" refers to a composition that includes one or more polymers. As a class, "polymers" include, but are not limited to, homopolymers, heteropolymers, copolymers, block polymers, and block copolymers, both natural and synthetic. Homopolymers contain one type of building block or monomer, while copolymers contain two or more types of monomers. An "oligomer" is a polymer that contains a small number of monomers, e.g., between 3 and 100 monomer residues. Thus, the term "polymer" includes oligomers. The terms "nucleic acid" and "nucleic acid analog" include nucleic acids as well as nucleic acid polymers and oligomers.

[0034] A polymer "comprises" or is "derived from" a specified monomer when the monomer has been incorporated into the polymer. Thus, the incorporated monomer contained in a polymer is not identical to the monomer prior to its incorporation into the polymer, at least in that a particular linking group has been incorporated into the polymer backbone or a particular group has been removed during the polymerization process. A polymer is said to contain a particular type of bond if that bond is present in the polymer. The incorporated monomer is a "residue." Typical monomers of nucleic acids or nucleic acid analogs are referred to as nucleotides.

[0035] By "non-reactive" in the context of chemical moieties, e.g., molecules, compounds, compositions, groups, moieties, ions, etc., it is meant that the moiety does not substantially react with other chemical moieties in its intended use. Non-reactive moieties are selected so that they do not interfere, or do not interfere significantly, with the intended use of the moiety, moiety, or group as a recognition reagent. In the context of the linker moieties described herein, they are non-reactive in that they do not interfere with the binding of the recognition reagent to the target template and do not interfere with the ligation of the recognition reagent on the target template.

[0036] As used herein, "alkyl" refers to a linear, branched, or cyclic hydrocarbon group containing from 1 to about 20 carbon atoms, such as, but not limited to, C1~3 , C 1~6 , C 1~10 "Alkyl" refers to groups including, but not limited to, linear and branched alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like. "Substituted alkyl" refers to alkyl substituted at one or more positions, such as 1, 2, 3, 4, 5, or even 6, where the substituents are attached at any available atom to produce a stable compound having substitutions as described herein. "Optionally substituted alkyl" refers to alkyl or substituted alkyl. "Halogen", "halogen compound", and "halo" refer to -F, -Cl, -Br, and / or -I. "Alkylene" and "substituted alkylene" refer to a divalent alkyl and a divalent substituted alkyl, respectively, including, but not limited to, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, or decamethylene. "Optionally substituted alkylene" refers to an alkylene or a substituted alkylene.

[0037] "Alkenyl" refers to a linear, branched, or cyclic hydrocarbyl group containing, for example, from 2 to about 20 carbon atoms, such as, but not limited to, a C alkene or alkenyl group having one or more, for example, 1, 2, 3, 4, or 5 carbon-carbon double bonds. 1~3 , C 1~6 , C 1~10"Substituted alkene" refers to an alkene substituted at one or more positions, e.g., 1, 2, 3, 4, or 5, where the substituents are attached at any available atom to produce a stable compound having substitution as described herein. "Optionally substituted alkene" refers to an alkene or substituted alkene. Similarly, "alkenylene" refers to a divalent alkene. Examples of alkenylene include, but are not limited to, ethenylene (-CH=CH-) and all stereoisomeric and conformational isomeric forms thereof. "Substituted alkenylene" refers to a divalent substituted alkene. "Optionally substituted alkenylene" refers to an alkenylene or substituted alkenylene.

[0038] "Alkyne" or "alkynyl" refers to a straight or branched unsaturated hydrocarbon having the indicated number of carbon atoms and at least one triple bond. Examples of (C2-C8)alkynyl groups include, but are not limited to, acetylene, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 1-hexyne, 2-hexyne, 3-hexyne, 1-heptyne, 2-heptyne, 3-heptyne, 1-octyne, 2-octyne, 3-octyne, and 4-octyne. Alkynyl groups can be unsubstituted or optionally substituted with one or more substituents as described herein below. The term "alkynylene" refers to a divalent alkyne. Examples of alkynylene include, but are not limited to, ethynylene, propynylene. "Substituted alkynylene" refers to a divalent substituted alkyne.

[0039] The term "alkoxy" refers to an -O-alkyl group having the indicated number of carbon atoms. For example, (C1-C6)alkoxy groups include -O-methyl (methoxy), -O-ethyl (ethoxy), -O-propyl (propoxy), -O-isopropyl (isopropoxy), -O-butyl (butoxy), -O-sec-butyl (sec-butoxy), -O-tert-butyl (tert-butoxy), -O-pentyl (pentoxy), -O-isopentyl (isopentoxy), -O-neopentyl (neopentoxy), -O-hexyl (hexyloxy), -O-isohexyl (isohexyloxy), and -O-neohexyl (neohexyloxy). "Hydroxyalkyl" refers to a (C1-C6)alkoxy group in which one or more of the alkyl group's hydrogen atoms have been replaced with an -OH group. 10 ) alkyl groups. Examples of hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2CH2CH2CH2OH, -CH2CH2CH2CH2CH2CH2OH, -CH2CH2CH2CH2CH2CH2OH, and branched forms thereof. The term "ether" or "oxygen ether" refers to an alkyl group where one or more carbon atoms of the alkyl group are replaced with an -O- group. The term ether includes those groups where P1 is a protecting group, -H, or a (C1-C10) alkyl, -CH2-(OCH2-CH2) q OP1 compounds are included. Exemplary ethers include polyethylene glycol, diethyl ether, methylhexyl ether, and the like.

[0040] "Heteroatom" refers to N, O, P and S. Compounds containing N or S atoms can be optionally oxidized to the corresponding N-oxide, sulfoxide or sulfone compounds. "Heterosubstituted" refers to organic compounds in any of the embodiments described herein, in which one or more carbon atoms are replaced with N, O, P, or S.

[0041] "Aryl", alone or in combination, refers to an aromatic ring system such as phenyl or naphthyl. "Aryl" also includes aromatic ring systems that may be optionally fused with a cycloalkyl ring. "Substituted aryl" refers to an aryl that is independently substituted with one or more substituents attached at any available atom to produce a stable compound, the substituents being as described herein. "Optionally substituted aryl" refers to an aryl or substituted aryl. "Arylene" refers to a divalent aryl, and "substituted arylene" refers to a divalent substituted aryl. "Optionally substituted arylene" refers to an arylene or substituted arylene. As used herein, the term "polycyclic aryl group" and related terms such as "polycyclic aromatic group" refer to a group composed of at least two fused aromatic rings. "Heteroaryl" or "hetero-substituted aryl" refers to an aryl group substituted with one or more heteroatoms such as N, O, P, and / or S.

[0042] "Cycloalkyl" refers to a monocyclic, bicyclic, tricyclic, or polycyclic, 3- to 14-membered ring system that is either saturated, unsaturated, or aromatic. The cycloalkyl group may be attached via any atom. Cycloalkyl also contemplates fused rings in which the cycloalkyl is fused to an aryl or heteroaryl ring. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl groups can be unsubstituted or optionally substituted with one or more substituents as described herein below. "Cycloalkylene" refers to a divalent cycloalkyl. The term "optionally substituted cycloalkylene" refers to a cycloalkylene substituted with one, two, or three substituents attached at any atom available to produce a stable compound, the substituents being as described herein.

[0043] "Carboxyl" or "carboxylic", when indicated, refers to a group having the indicated number of carbon atoms, terminated with a -C(O)OH group, and thus having the structure -RC(O)OH, where R is a divalent organic group containing a linear, branched or cyclic hydrocarbon. Non-limiting examples of these include C 1~8 Included are carboxyl groups, such as ethanoic, propanoic, 2-methylpropanoic, butanoic, 2,2-dimethylpropanoic, pentanoic, etc. "Amine" or "amino" refers to a group having the indicated number of carbon atoms, where indicated, terminated with an -NH2 group, and thus having the structure -R-NH2, where R is an unsubstituted or substituted divalent organic group including linear, branched or cyclic hydrocarbons, and optionally containing one or more heteroatoms.

[0044] The above combinations include the above suitable combinations, for example, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkynyl, alkyl ... It refers to arylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl. As an example, "arylalkylene" refers to a divalent alkylene in which one or more hydrogen atoms in the alkylene group are replaced with an aryl group, such as a (C3-C8)aryl group. Examples of (C3-C8)aryl-(C1-C6)alkylene groups include, but are not limited to, 1-phenylbutylene, phenyl-2-butylene, 1-phenyl-2-methylpropylene, phenylmethylene, phenylpropylene, and naphthylethylene. The term "(C3-C8)cycloalkyl-(C1-C6)alkylene" refers to a divalent alkylene in which one or more hydrogen atoms in the C1-C6 alkylene group are replaced with a (C3-C8)cycloalkyl group.Examples of (C3-C8)cycloalkyl-(C1-C6)alkylene groups include, but are not limited to, 1-cycloproylbutylene, cyclopropyl-2-butylene, cyclopentyl-1-phenyl-2-methylpropylene, cyclobutylmethylene, and cyclohexylpropylene.

[0045] An "amino acid" has the structure H2N-C(R)-C(O)OH, where R is a side chain, e.g., an amino acid side chain. An "amino acid residue" refers to the remainder of an amino acid, which when incorporated into a chain of amino acids, e.g., into a recognition reagent disclosed herein, has, e.g., the structure -NH-C(R)-C(O)-, H2N-C(R)-C(O)- (if at the N-terminus of a polypeptide), or -NH-C(R)-C(O)OH (if at the C-terminus of a polypeptide). An "amino acid side chain" is the side chain of an amino acid, including proteinogenic or non-proteinogenic amino acids. An amino acid has the structure: [ka] having where R is an amino acid side chain. Non-limiting examples of amino acid side chains are shown in Figure 3. Glycine (H2N-CH2-C(O)OH) has no side chain.

[0046] "Peptide nucleic acid" refers to a nucleic acid analog, or DNA or RNA mimic, in which the sugar phosphodiester backbone of DNA or RNA is replaced with N-(2-aminoethyl)glycine units. Gamma PNA (γPNA) has the following structure: [ka] wherein at least one of R1 or R2 attached to the γ carbon is not hydrogen, so that the γ carbon is a chiral center. When R1 and R2 are hydrogen (N-(2-aminoethyl)-glycine backbone), or are the same, there is no such chirality about the γ carbon. Incorporated PNA or γPNA monomers, [ka] are referred to herein as PNA or gamma PNA "residues" in terms of the remaining structure after integration into the oligomer, and each residue has an R group that is the same or different from its bases (nucleobases), e.g., adenine, guanine, cytosine, thymine and uracil bases, or other bases, e.g., the monovalent and divalent bases described herein, so that, like DNA or RNA, the order of the bases on a PNA is its "sequence." The sequence of nucleobases in a nucleic acid or nucleic acid analog oligomer or polymer, e.g., a PNA or gamma PNA oligomer or polymer, binds by nucleobase pairing to a complementary sequence of adenine, guanine, cytosine, thymine and / or uracil residues in the nucleic acid or nucleic acid analog strand, in a Watson-Crick or Watson-Crick-like manner, essentially similar to double-stranded DNA or RNA.

[0047] "Guanidine" or "guanidinium" groups can be added to the recognition reagent to increase solubility and / or bioavailability. Because PNAs are generated in a manner similar to synthetic peptides, a simple method for adding guanidine groups is to add one or more terminal arginine (Arg) residues to the N-terminus and / or C-terminus of the PNA, e.g., γPNA recognition reagent. Similarly, arginine side groups, [ka] or a guanidine-containing moiety, e.g. [ka] where n can be, for example, but not limited to, in the range of 1 to 5, or a salt thereof, attached to a recognition reagent backbone as described herein. A guanidine-containing group is a group that includes a guanidine moiety and can have fewer than 100 atoms, fewer than 50 atoms, e.g., fewer than 30 atoms. In one embodiment, the guanidine-containing group has the structure: [ka] having wherein L is a linker according to any embodiment described herein, e.g., a non-reactive aliphatic hydrocarbyl linker, e.g., a methylene, ethylene, trimethylene, tetramethylene, or pentamethylene linker. In some embodiments, the guanidine-containing group has the structure: [ka] having Here, n is 1 to 5, and for example, the guanidine group may be arginine.

[0048] "Nucleobases" include the primary nucleobases, i.e., adenine, guanine, thymine, cytosine, and uracil, as well as modified purine and pyrimidine bases, such as, but not limited to, hypoxanthine, xanthene, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, and 5-hydroxymethylcytosine. Figures 4 and 5A-5C also depict non-limiting examples of nucleobases, including monovalent nucleobases (e.g., adenine, cytosine, guanine, thymine, or uracil, which bind to one strand of a nucleic acid or nucleic acid analog), and divalent nucleobases (e.g., JB1-JB16, described herein) that simultaneously bind to complementary nucleobases on two strands of a nucleic acid, and "clamp" nucleobases, such as "G-clamps," which bind to complementary nucleobases with increased strength. Additional purine, purine-like, pyrimidine and pyrimidine-like nucleobases are known in the art, for example, as disclosed in U.S. Patent Nos. 8,053,212, 8,389,703 and 8,653,254. For the bivalent nucleobases JB1-JB16 shown in FIG. 5A, Table A shows the specificity of the various nucleobases. In particular, the JB1-JB4 series binds complementary bases (CG, GC, AT and TA), while JB5-JB16 binds mismatches and can therefore be used to bind two strands of matched and / or mismatched bases. Bivalent nucleobases are described in further detail in U.S. Patent Publication No. 20160083434A1 and International Publication No. WO / 2018 / 058091, both of which are incorporated herein by reference.

[0049] [Table A]

[0050] As used herein, "JB# nucleobase", e.g., "JB4 nucleobase", refers to all nucleobases having the JB4 designation, representing C / G (linked G / C), including JB4, JB4b, JB4c, JB4d, and JB4e. Exemplary γPNA structures that are not end-modified with aryl groups in the manner described herein, but may be end-modified as described herein, are disclosed in WO 2012 / 138955, which is incorporated herein by reference. As shown herein, miniPEG γPNAs include one or more groups that include a poly(ethylene glycol) (PEG, polyoxyethylene) moiety.

[0051] Complementary refers to the ability of polynucleotides (nucleic acids) to hybridize (bind) with each other and form interstrand base pairs. Base pairs are formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair (hybridize or bind) in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of a duplex. When using RNA rather than DNA, uracil, rather than thymine, is the complementary base to adenosine. Two sequences containing complementary sequences can hybridize if they form a duplex under certain conditions, such as in water, saline (e.g., normal saline or 0.9% w / v saline) or phosphate buffered saline, or other stringency conditions, such as, but not limited to, 0.1×SSC (saline sodium citrate) to 10×SSC, where 1×SSC is 0.15 M NaCl and 0.015 M sodium citrate in water. Hybridization of complementary sequences is affected, for example, by salt concentration and temperature, with increasing mismatch and increasing stringency resulting in higher melting temperatures (T m) is reduced. Perfectly matched sequences are said to be "perfectly complementary," although it is possible that one sequence (e.g., a target sequence in an mRNA) is longer than the other, as is the case for the small recognition reagents described herein with respect to the much longer target sequences they link to, such as mRNAs containing repeat extensions. Two complementary strands of nucleic acid bind in an antiparallel orientation, with one strand in a 5' to 3' orientation and the other in a 3' to 5' orientation. PNAs allow both parallel and antiparallel orientations, but antiparallel binding is preferred for gamma PNAs.

[0052] According to one aspect of the invention, a gene recognition reagent is provided. In some embodiments, the recognition reagent is self-concatenating, meaning that it contains a linking group, i.e., a terminal group, that either covalently binds when hybridizing to adjacent sequences on a target nucleic acid, or non-covalently binds, e.g., by π-stacking. The recognition reagent contains three or more, e.g., 3-10 or 3-8 adjacent nucleic acid or nucleic acid analog monomer residues, with a terminal group that contains a sequence of nucleic acid bases for hybridizing (binding) to a repeat expansion sequence associated with a repeat expansion disease, e.g., self-ligating or π-stacking, to target a double-stranded RNA hairpin sequence. In the case of polyQ disease, rCAG exp The double stranded sequence of the hairpin formed from the sequence is the target sequence, and the reagent has a sequence of bivalent nucleobases selected from the following: EIF or (EIF) n (where n is an integer equal to or greater than 2, e.g., 2, 3, 4, or 5), e.g., EIFEIF, IFE, or (IFE) n (where n is an integer equal to or greater than 2, e.g., 2, 3, 4, or 5), e.g., IFEIFE, or FEI, or (FEI) n(where n is an integer equal to or greater than 1, e.g., 2, 3, 4, or 5), e.g., FEIFEI, where E is a divalent nucleobase, e.g., JB3 or JB3b, linkage C / G (Watson strand / Crick strand), F is a divalent nucleobase, e.g., JB4, JB4b, JB4c, JB4d, or JB4e, linkage G / C, and I is a divalent nucleobase, e.g., JB6 or JB6b, linkage A / A, and thus can bind to both hybridized strands of a hairpin formed from a CAG repeat, as shown in FIG. 1.

[0053] The recognition reagents described herein combine the characteristics of small molecules, such as low molecular weight, ease of large-scale production, low production costs, cell membrane permeability, and desirable pharmacokinetics, with sequence-specific recognition of oligonucleotides by Watson-Crick base pairing. Ligation of oligomeric recognition reagents has been demonstrated for both self-ligating and π-stacking ligation methods and is described according to examples that are intended to be illustrative in all respects and not limiting. Thus, the present invention is capable of many variations in its detailed implementation that a person skilled in the art can derive from the description contained herein.

[0054] An example application of the recognition reagents described herein is in the treatment of genetic diseases involving small sequence repeat expansions, such as those listed in Table B.

[0055] [Table B]

[0056] Based on Table B, exemplary sequences of bivalent nucleobases of recognition reagents targeting the described gene products, including sequences in the 5' to 3' direction relative to the sense strand, are presented in Table C. It should be noted that, depending on their sequences, not all repeat sequences form hairpin structures under normal conditions, but can be induced into triplex "hairpin" structures by the listed recognition reagents. It should also be noted that the sequences listed in Table C are merely exemplary, and it is expected that other sequences will form triplex structures, depending on the alignment of the folded sequences in the natural hairpin structure or the hairpin structure induced by the recognition reagent. Also, due to the repeat nature of the sequences, in the case of triplet repeats, three different frameshifts are useful for each sequence (Table C, (GAA) n (See the third column of FIG. 1), and in the case of a tetranucleotide repeat, four different frameshifts are useful. Thus, in the case of a triplet sequence, the permutation of the duplex binding alignments and the ability to frameshift the recognition reagent within each alignment (e.g., the rCAG exp The alignment within the sequence (EIF, IFE, and FEI) results in 9 permutations of the unit recognition reagent, which can be repeated in the recognition reagent. For example, the sequence (GAA) n In the case of (GAA), there is no folding alignment predicted to form a hairpin duplex under normal conditions, but the three different sequences are predicted to be capable of forming a triplex structure. In Table C, the only repeat sequence that shows all permutations is (GAA). nFor other repeats, only exemplary sequences are presented. In particular, due to the repeat structure, any of the sequences presented in Table C may be repeated, for example, 2-5x, e.g., G / AA / AA / G, also referred to as G / AA / AA / GG / AA / AA / G, and 13-6-14 (JB13 series-JB6 series-JB14 series) also includes 13-6-14-13-6-14. In Table C, the nucleobase sequences are first identified by the target nucleobase to which they are bound (e.g., JB4 binds G / C), and are also identified by the "JB" reference number, e.g., "4", which refers to "JB4", including JB4, JB4b, JB4c, JB4d, and JB4e.

[0057] [Table C-1] [Table C-2]

[0058] In Table C, the unit recognition reagent target sequence (bound bases) lists as "B1 / B2" each base pair of the two strands bound by a single divalent nucleobase of the recognition reagent, where B1 is a base from the first strand and B2 is a base from the second strand when bound by the divalent nucleobase of the recognition reagent. Thus, the sequence (CAG) n In the case of the above, the sequence of the target unit is C / GA / AG / C, which refers to an antiparallel sequence of the sequence 5'-CAG-3', and the sequence, (CCG) n In the case, the sequence of the second alignment of the target sequence is C / GG / CC / C, which refers to the alignment of 5'-CCG-3' and antiparallel 5'-CGC-3', while the sequence C / GC / CG / C refers to the antiparallel alignment of the sequence 5'-CCG-3'.

[0059] A "unit target sequence" in the context of binding of a recognition reagent is the shortest repeat sequence found in a repeat nucleobase sequence in a target nucleotide sequence, or a repeat double-stranded nucleobase sequence, containing mismatches, aligned in a double-stranded sequence with two strands of the same or different nucleic acid molecules, e.g., when bound in a triplex structure by a bivalent recognition reagent as described herein.

[0060] In one embodiment, a recognition reagent is provided that includes a peptide nucleic acid or gamma peptide nucleic acid backbone having a first end and a second end, prepared from three or more, e.g., 3-10, or 3, 4, 5, 6, 7, 8, 9, or 10, or 3-8 PNA or gamma PNA backbone residues, a sequence of nucleobases consecutively bound or linked to a plurality of nucleic acid or nucleic acid analog backbone residues, an -SH, -OH, or -SS-Lg moiety at the first end of the backbone, and a -C(O)-S-Lg or -C(O)-O-Lg moiety at the second end of the backbone (the leaving group Lg is linked to the backbone by an ester or thioester bond), where the sequence of nucleobases is complementary to a target unit sequence or two or more successive repeats (two or more direct repeats of a particular sequence, without gaps) of a target unit sequence within a target sequence in a nucleic acid, such that the recognition modules ligate to each other when bound to adjacent sequences of the target sequence. In one embodiment, Lg is biocompatible and / or non-toxic. Non-limiting examples of Lg include substituted or unsubstituted (C1-C8) alkyl, substituted or unsubstituted (C3-C8) aryl, (C3-C8) aryl (C1-C6) alkylene, (C1-C8) carboxy, optionally substituted with an amino acid side chain, or a guanidine-containing group, or [ka] Includes: wherein o is 1 to 20, each R6 is independently an amino acid side chain, and R7 is -OH or -NH2.

[0061] In another aspect, there is provided a recognition reagent comprising a nucleic acid or nucleic acid analog backbone having a first end and a second end and prepared from three or more, e.g., 3-10, or 3, 4, 5, 6, 7, 8, 9, or 10, or 3-8 nucleic acid or nucleic acid analog backbone residues, optionally conformationally preorganized, a sequence of nucleobases consecutively bound or linked to a plurality of the nucleic acid or nucleic acid analog backbone residues, a first aryl moiety linked to the first end of the nucleic acid or nucleic acid backbone, and a second aryl moiety, which may optionally be identical to the first aryl moiety, linked to the second end of the nucleic acid or nucleic acid backbone. The aryl moieties are independently 2-5 ring fused polycyclic aromatic moieties, e.g., substituted or unsubstituted aryl or heteroaryl moieties having 2-5 fused rings, such as, but not limited to, unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B2), mangosteen, or mangiferin, which may be the same or different, and in some embodiments are the same. provided that each is capable of stacking with the aryl moiety of an adjacent recognition reagent when the recognition reagents hybridize to adjacent sequences of the target nucleic acid. The recognition reagents can bind to both strands of a hairpin formed from an expanded repeat associated with a repeat expansion disease, such as polyQ disease, e.g., as listed in Table B. In one embodiment, the recognition reagents have the sequence EIF or (EIF) as described above. n (wherein n is an integer equal to or greater than 2, e.g., 2, 3, 4, or 5), such as EIFEIF, IFE, or (IFE) n (where n is an integer equal to or greater than 2, e.g., 2, 3, 4, or 5), e.g., IFEIFE, or FEI, or (FEI) n(wherein n is an integer greater than or equal to 2, e.g., 2, 3, 4, or 5), e.g., for use in combining CAG repeats with FEIFEI.

[0062] In one embodiment, the recognition reagent is self-ligating and has the structure: [ka] having wherein X is S or O, n is an integer from 1 to 6, m is an integer from 0 to 4, and R1 and R2 are each independently H, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] -CH2-(OCH2-CH2) is a straight chain or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, (C3-C8) cycloalkyl (C1-C6) alkylene, optionally substituted with ethylene glycol units containing 1 to 50 ethylene glycol moieties; q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] sNHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R3 is H or a leaving group, which in one embodiment is biocompatible and / or non-toxic, e.g., substituted or unsubstituted (C1-C8) alkyl, substituted or unsubstituted (C3-C8) aryl, (C3-C8) aryl (C1-C6) alkylene (C1-C8) carboxy, a guanidine-containing group, optionally substituted with an amino acid side chain, or [ka] where o is 1 to 20, each R6 is independently an amino acid side chain, R7 is -OH or -NH2, and R4 is (C1 to C 10 ) divalent hydrocarbon or (C1-C2) substituted with one or more N or O moieties, such as -O-, -OH, -C(O)-, -NH-, -NH2, -C(O)NH- 10 ) divalent hydrocarbon, R5 is -OH, -SH or a disulfide protecting group, and each of R is independently a nucleobase to produce a sequence of nucleobases complementary to a target sequence of nucleobases in the target nucleic acid such that each of the plurality of recognition modules binds to a target sequence of nucleobases on the template nucleic acid and ligates to one another. In one embodiment, R5 has the structure -SH, -OH, or -SS-R8, where R8 is one or more amino acid residues, amino acid side chains, linear, branched or hetero-substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl(C1-C6) alkylene, (C3-C8) cycloalkyl(C1-C6) alkylene. In one embodiment, R1 or R2 is an amino acid side chain or a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5. In one embodiment, R1 and R2 are different, and R1 is H and R2 is not H, or R2 is H and R1 is not H. For binding to natural nucleic acids, such as RNA or DNA, R1 may be H and R2 is not H, thereby forming a "right-handed" L-γPNA. For example, a "left-handed" D-γPNA, where R2 is H and R1 is not H, will not bind to natural nucleic acids. In one embodiment, the recognition reagent comprises one or more guanidine-containing groups, such as [ka] where n=1, 2, 3, 4, or 5.

[0063] In one embodiment, R1 or R2 is -(OCH2-CH2) q OP1, -(OCH2-CH2) q -NHP1, -(SCH2-CH2) q -SP1, -(OCH2-CH2)r-OH, -(OCH2-CH2) r -NH2, -(OCH2-CH2) r -NHC(NH)NH2, or -(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2 substituted (C1-C6)alkyl, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, r is an integer from 1 to 50, and s is an integer from 1 to 50.

[0064] A recognition reagent terminated in an aryl group has the ability to link as a result of non-covalent bonding, e.g., π-stacking, of the aryl groups of immediately adjacent hybridized recognition reagents. Thus, in another embodiment, a recognition reagent having the structure: [ka] A recognition reagent (recognition module) is provided having the following structure: wherein R is independently a nucleobase and each of R can be the same or a different nucleobase; n is an integer ranging from 1 to 6, for example, 1, 2, 3, 4, 5, or 6; each B is independently a ribose-5-phosphate residue, a deoxyribose-5-phosphate residue, or a nucleic acid analog backbone residue, in one embodiment a backbone residue of a conformationally preorganized nucleic acid analog, e.g., gamma PNA or LNA; L is independently a linker, e.g., a non-reactive linker or a non-reactive, non-bulky linker, each of the L's can be the same or different, and Each Ar is independently a 2-5 ring fused polycyclic aromatic moiety, e.g., a substituted or unsubstituted aryl or heteroaryl moiety having 2-5 fused rings, such as, but not limited to, unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B2), mangosteen, or mangiferin, which may be the same or different, and in some embodiments are the same. In some embodiments, each Ar stacks with an Ar group of an adjacent recognition reagent when the recognition reagents hybridize to adjacent sequences of a target nucleic acid.

[0065] A moiety of a compound, e.g., an aryl moiety or a nucleobase, is covalently bonded to the recognition reagent backbone and is therefore said to be "linked" to the backbone. Depending on the chemistry used to prepare the compound, the bond may be direct or may be via a "linker," which is a moiety that covalently bonds two other moieties or groups. In one embodiment, the terminal aromatic (aryl) group is attached to the recognition reagent through a linker. The linker is a non-reactive moiety that links the aromatic group to the backbone of the recognition reagent and, in some embodiments, is a 1-10 carbon atom (C1-C2) optionally substituted with a heteroatom, e.g., N, S, or O. 10 ), or a non-reactive bond, such as an amide bond (peptide bond) formed by reacting an amine with a carboxyl group. 10 Examples of alkylene include linear or branched alkylene (divalent) moieties, which may optionally include cyclic moieties, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, or decamethylene moieties (i.e., -CH-[CH]), which may optionally include amide bonds. n -, where n=1-9). The linker is not bulky in that it does not substantially sterically block or otherwise interfere with the binding of the recognition reagent to the target nucleic acid and does not interfere with the linkage of the recognition reagent on the target nucleic acid. The linker is a non-bulky moiety resulting from the linkage of the aromatic group and backbone of the recognition reagent, e.g. [ka] or, in one non-limiting example, resulting from the attachment of an acetate-substituted aryl compound (A), such as pyrene-1-acetic acid, to a Dab (n=1), Orn (n=2), or Lys (n=3) residue. [ka] It is.

[0066] In further embodiments, the linker or linking group is an organic moiety that connects, e.g., covalently bonds, two portions of a compound, such as, but not limited to, in the context of the present invention, an aromatic group to the backbone of a recognition reagent, a nucleobase to a nucleic acid or nucleic acid analog backbone, and / or a guanidinium group to a recognition reagent.A linker is typically a direct bond or a unit such as an atom such as oxygen or sulfur, C(O), C(O)NH, SO, SO2, SO2NH or a chain of atoms, including, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylhetero ... and heteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, where one or more carbons, e.g., methylene or methylidyne (-CH=), may optionally be an internal or terminal heteroatom, e.g., O, S, or N, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle.In one embodiment, the linker comprises about 5-25 atoms, e.g., 5-20, 5-10, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms, or a total of 1-10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C and heteroatoms, e.g., O, P, N, or S atoms.

[0067] For linking with PNA, e.g., γPNA, suitable and available linkers are those that react an amine with a carboxyl group to form an amide bond, e.g., using well-known peptide synthesis chemistry to add an amino acid to the recognition reagent, which may be pre-modified with a chemical moiety, e.g., an aryl moiety, or a guanidine group, e.g., as shown in the examples below, by adding an aryl-modified amino acid to link a pyrene aryl moiety to the recognition reagent, and using arginine to provide a guanidine group. Linking to non-peptide nucleic acid analogs can be achieved by linking an amine-modified aromatic moiety to the recognition reagent, e.g., via a terminal phosphate, using any suitable linking chemistry as is widely known, e.g., carbodiimide chemistry, e.g., EDC (EDAC, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride).

[0068] When linking an aromatic group to the backbone of the recognition reagent, the linker is of an appropriate size or length to position the aromatic group in a position for π-π stacking during linkage of the recognition reagent on the target nucleic acid sequence as described herein.

[0069] In a further embodiment, the recognition reagent has the structure: [ka] where each R is independently a nucleobase and each R can be the same or a different nucleobase; n is an integer ranging from 1 to 6, for example, 1, 2, 3, 4, 5, or 6; R1 and R2 are each independently H, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] , unsubstituted or substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, or (C3-C8) cycloalkyl (C1-C6) alkylene, -CH2-(OCH2-CH2) q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(OCH2-CH2-O) q -SP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH) r -SS[CH2CH2] s NHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, r is an integer from 1 to 50, s is an integer from 1 to 50, and in one embodiment, R1 and R2 are different, R1 is H and R2 is not H, or R2 is H and R1 is not H. R 10 or R 11 On the other hand, R 12 , R 13 , or R 14one of which is -L-R3, where each R3 is independently a 2-5 ring fused polycyclic aromatic moiety, e.g., a substituted or unsubstituted aryl or heteroaryl moiety having 2-5 fused rings, such as, but not limited to, unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, ace ... phenylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B2), mangosteen, or mangiferin, which may be the same or different, and in some embodiments are the same, and in some cases stack with the R3 group of the adjacent recognition reagent when the recognition reagent hybridizes to the adjacent sequence of the target nucleic acid, wherein L is a linker, e.g., a non-reactive linker or a non-reactive, non-bulky linker, and each of the L's can be the same or different and is an amino acid residue, or a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl alkyl, aryl alkenyl, aryl alkynyl, heteroaryl alkyl, heteroaryl alkenyl, heteroaryl alkynyl, heterocyclyl alkyl, heterocyclyl alkenyl, heterocyclyl alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylaryl alkyl, alkylaryl alkenyl, alkylaryl alkynyl, alkenylaryl alkyl, alkenylaryl alkenyl, alkenylaryl alkynyl, alkynylaryl alkyl, alkynylaryl alkenyl, alkynylaryl alkynyl, alkylheteroaryl alkyl, alkylheteroaryl alkenyl, alkylheteroaryl alkynyl, alkenylhetero ... aryl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, one or more carbons, e.g., methylene or methylidyne (-CH=), may optionally be interrupted or terminally replaced by a heteroatom, e.g., O, S, or N, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle; And R 10 , R 11 , R 12 , R 13 , and R 14the remainder are each independently H, one or more adjacent amino acid residues, a guanidine-containing group, an amino acid side chain, a straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, (C3-C8) cycloalkyl (C1-C6) alkylene, optionally substituted with ethylene glycol units containing 1 to 50 ethylene glycol moieties, -CH2-(OCH2-CH2) q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, r is an integer from 1 to 50, and s is an integer from 1 to 50.

[0070] In one embodiment, R4 and R7 are -L-R3, and in another embodiment, R4 and R7 are -L-R3 and R11 and R14 are Arg. In one embodiment, the linker comprises about 5-25 atoms, e.g., 5-20, 5-10, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms, or a total of 1-10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C and heteroatoms, e.g., O, P, N, or S atoms. In another embodiment, one or more of R1, R2, R 10 , R 11 , R12 , R 13 , or R 14 is -(OCH2-CH2) q OP1, -(OCH2-CH2) q -NHP1, -(SCH2-CH2) q -SP1, -(OCH2-CH2) r -OH, -(OCH2-CH2) r -NH2, -(OCH2-CH2) r -NHC(NH)NH2, or -(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2 substituted (C1-C6)alkyl, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, r is an integer from 1 to 50, and s is an integer from 1 to 50.

[0071] In yet another embodiment, the recognition reagent comprises a PNA backbone and thus has the structure: [ka] where n is an integer ranging from 1 to 8, inclusive; m is an integer ranging from 1 to 5, for example 1 to 3, inclusive; R2 is a guanidine-containing group, e.g. [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] , unsubstituted or substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, or (C3-C8) cycloalkyl (C1-C6) alkylene, -CH2-(OCH2-CH2) q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(OCH2-CH2-O) q -SP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R3 is an unsubstituted fused-ring polycyclic aromatic moiety such as pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene; R 11 , R 13 , and R 14 each independently represents H, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; an amino acid side chain, or one or more adjacent amino acid residues, such as one or more Arg residues. In one embodiment, R3 is pyrene.

[0072] In another embodiment, R2 is -CH2-(OCH2-CH2) r -OH, where r is an integer ranging from 1 to 50, e.g., 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and in Example 2, is 1. In another embodiment, one or more R2, R 11 , R 13 , or R 14 is -(OCH2-CH2) q OP1, -(OCH2-CH) q -NHP1, -(SCH2-CH2) q -SP1, -(OCH2-CH2) r -OH, -(OCH2-CH2) r -NH2, -(OCH2-CH2) r -NHC(NH)NH2 or -(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2 substituted (C1-C6)alkyl, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer of 0 to 50, r is an integer of 1 to 50, and s is an integer of 1 to 50.

[0073] Some of the PNA-based recognition reagents are shown without chirality, and in one example, the γ carbon (where R1 and R2 are attached) is in the (R) orientation, where R2 is H and R1 is not H, or the γ carbon is in the (S) orientation, for example, where R1 is H and R2 is not H. Additionally, in one example, when present, R 10 , R 11 , R 12 , R 13 , and / or R 14At position 1, one or more, or all, of the chiral amino acid residues may be an L-amino acid. 10 , R 11 , R 12 , R 13 , and / or R 14 At positions, one or more or all of the chiral amino acid residues can be D-amino acids.

[0074] Pharmaceutically acceptable salts of any of the above are also provided.

[0075] Any pharmaceutically acceptable salt of the compounds described herein can also be used in the methods described herein.The pharmaceutically acceptable salt forms of the compounds described herein can be prepared by conventional methods known in the pharmaceutical arts, and may include as veterinary acceptable salts.For example, but not limited to, if a compound contains a carboxy group, its suitable salt can be formed by reacting the compound with a suitable base to provide the corresponding base addition salt.Non-limiting examples include alkali metal hydroxides, such as potassium hydroxide, sodium hydroxide and lithium hydroxide, alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide, alkali metal alkoxides such as potassium ethanolate and sodium propanolate, and various organic bases such as piperidine, diethanolamine, and N-methylglutamine.

[0076] Non-limiting examples of pharma- ceutically acceptable base salts include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts. Salts derived from pharma- ceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine, and tris-(hydroxymethyl)-methylamine (tromethamine).

[0077] Non-limiting examples of pharma- ceutically acceptable acid salts include acetate, adipate, alginate, alginate, aspartate, benzoate, besylate (benzenesulfonate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, fumarate, galacterate, galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, and the like. Salts include, but are not limited to, acetic acid salts, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, and phthalate.

[0078] Complex salt forms are also considered to be pharma- ceutically acceptable salts. Common non-limiting examples of complex salt forms include bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium, and trihydrochloride.

[0079] Thus, as used herein, "pharmaceutically acceptable salts" is intended to mean active moieties (drugs) including salt forms of any of the compounds described herein, the salt forms preferably imparting improved and / or desired pharmacokinetic / pharmodynamic properties of the compounds described herein.

[0080] The compositions described herein can be administered by any effective route.Examples of delivery routes include, but are not limited to, topical, such as epicutaneous, inhalation, enema, ophthalmic, aural and intranasal delivery, enteral, such as orally, by gastric tube and rectally, and parenteral, such as intravenous, intraarterial, intramuscular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal, transdermal, iontophoresis, transmucosal, epidural and intravitreal, with oral, intravenous, intramuscular and transdermal approaches being preferred in many cases.Suitable dosage forms can include single-dose or multi-dose vials or other containers, such as medical syringes, that contain compositions that contain active moieties useful for treating repeat expansion disease, as described herein.

[0081] Dosage regimens can be adjusted to provide the optimum desired response (e.g., therapeutic or prophylactic response). For example, a single bolus may be administered, multiple divided doses may be administered over an extended period of time, or the composition may be administered in a continuous or pulsatile manner, with the dose or subdoses being proportionally reduced or increased at regular intervals, e.g., every 10, 15, 20, 30, 45, 60, 90, or 120 minutes, every 2-12 hours daily, or every other day, etc., as indicated by the requirements of the therapeutic situation. In some cases, it may be particularly advantageous to formulate compositions, e.g., parenteral or inhalation compositions, in unit dosage forms for ease of administration and uniformity of dosage. The specifications for the unit dosage forms are determined by and directly depend on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compounds for the treatment of an individual's hypersensitivity.

[0082] Useful dosage forms include intravenous, intramuscular or intraperitoneal solution, oral tablet or liquid, topical ointment or cream and transdermal device (e.g., patch).In one embodiment, the compound is a sterile solution that contains active moiety (drug or compound) and solvent such as water, saline, lactated Ringer's solution or phosphate buffered saline (PBS).Additional excipients such as polyethylene glycol, emulsifiers, salts and buffers can be included in the solution.

[0083] Therapeutic / pharmaceutical compositions are prepared in accordance with acceptable compounding procedures as described, for example, in Remington: The Science and Practice of Pharmacy, 21st edition, ed. Paul Beringer et al., Lippincott, Williams & Wilkins, Baltimore, MD Easton, Pa. (2005) (see, e.g., Chapters 37, 39, 41, 42, and 45 for examples of powder, liquid, parenteral, intravenous, and oral solid formulations and methods of making such formulations).

[0084] Dosage regimens can be adjusted to provide the optimum desired response (e.g., therapeutic or prophylactic response). For example, a single bolus may be administered, multiple divided doses may be administered, or the composition may be administered in a continuous or pulsatile manner, with doses or subdoses administered at regular intervals, e.g., every 10, 15, 20, 30, 45, 60, 90, or 120 minutes, every 2 to 12 hours daily, or every other day, with proportional reductions or increases as desired by the exigencies of the therapeutic situation. In some cases, it may be particularly advantageous to formulate compositions, such as parenteral or inhalation compositions, in unit dosage forms for ease of administration and uniformity of dosage. The details of the unit dosage forms are dictated by and directly depend on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the technology of compounding such active compounds for the treatment of hypersensitivity in individuals.

[0085] Useful dosage forms include intravenous, intramuscular, or intraperitoneal solutions, oral tablets or liquids, topical ointments or creams, and transdermal devices (e.g., patches).In one embodiment, the compound is a sterile solution that includes an active moiety (drug, or compound) and a solvent such as water, saline, lactated Ringer's solution, or phosphate-buffered saline (PBS).Additional excipients such as polyethylene glycol, emulsifiers, salts, and buffers may be included in the solution.

[0086] In addition to the gene recognition reagents, an aspect of the invention also provides a method of binding a nucleic acid containing an expanded repeat associated with a repeat expansion disease, comprising contacting the nucleic acid containing the expanded repeat with any of the embodiments of the gene recognition reagents described herein. In one embodiment, the method is performed in vitro or ex vivo. In another embodiment, the method is performed in vivo by administering to a patient a suitable pharmaceutical formulation containing the gene recognition reagent in an amount effective to knock down expression of a gene having an expanded repeat or to treat the patient.

[0087] In another embodiment, in a sample obtained from a patient, (CAG) n A method is provided for identifying the presence of nucleic acid containing an expanded repeat associated with a repeat expansion disease, such as. The method comprises contacting a nucleic acid sample obtained from a patient with a gene recognition reagent according to any embodiment as described herein. The binding and ligation of the gene recognition reagent then occurs in the presence of a target sequence in the nucleic acid in the sample, and thus the binding and ligation are indicative of the presence of the target sequence in the nucleic acid in the sample. The binding and ligation of the gene recognition reagent can be detected and / or quantified using any effective method. The presence of a nucleic acid containing an expanded repeat in the target sequence is associated with a repeat expansion disease, in which case the patient can be treated for the repeat expansion disease, for example, by administering to the patient a pharmaceutical dosage form comprising the gene recognition reagent described herein.

[0088] Thus, methods of treating patients with diseases associated with expanded repeats of nucleotide sequences are provided. Exemplary diseases are those listed in Table B or polyQ diseases, such as Huntington's disease, DRPLA (dentatorubral-pallidoluysian atrophy), SBMA (spinal-bulbar muscular atrophy), SCA1 (spinocerebellar ataxia type 1), SCA2 (spinocerebellar ataxia type 2), SCA3 (spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (spinocerebellar ataxia type 6), SCA7 (spinocerebellar ataxia type 7), and SCA17 (spinocerebellar ataxia type 17). The disease may be a polyQ disease, such as for Huntington's disease, (CAG) n The patient is treated by administering to the patient a composition or pharmaceutical dosage form containing a gene recognition reagent as described herein that is selected to bind a repetitive sequence characteristic of a particular disease, such as leukemia, breast cancer, or breast cancer. The pharmaceutical composition is administered to a patient in an amount and dosage regimen effective for treating the disease.Therefore, the use of the composition comprising the gene recognition reagent as described herein is also provided for treating diseases associated with expanded repeats of nucleotide sequences, such as PolyQ diseases, such as Huntington's disease, DRPLA (dentatorubral-pallidoluysian atrophy), SBMA (spinal-bulbar muscular atrophy), SCA1 (spinocerebellar ataxia type 1), SCA2 (spinocerebellar ataxia type 2), SCA3 (spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (spinocerebellar ataxia type 6), SCA7 (spinocerebellar ataxia type 7), and SCA17 (spinocerebellar ataxia type 17).

[0089] In some embodiments, the disclosure provides a compound comprising: a) a series of peptide nucleic acid (PNA) units comprising i) a first unit, ii) a final unit, and iii) at least one intermediate unit between the first unit and the final unit, each unit in the series of units comprising A) a backbone moiety, where 1) the backbone moiety of the first unit is covalently bonded to the backbone moiety of one other unit, 2) the backbone moiety of the final unit is covalently bonded to the backbone moiety of one other unit, and 3) the backbone moiety of each intermediate unit is covalently bonded to the backbone moieties of two other units; and B) a divalent nucleobase covalently bonded to the backbone moiety, b) a first aryl moiety covalently bonded to the first unit, and c) a final aryl moiety covalently bonded to the final unit.

[0090] In some embodiments, the disclosure provides compounds comprising: a) a series of PNA units comprising i) a first unit, ii) a terminal unit, and iii) at least one intermediate unit between the first unit and the terminal unit, each unit in the series of units comprising A) a backbone moiety, where 1) the backbone moiety of the first unit is covalently bonded to the backbone moiety of one other unit, 2) the backbone moiety of the terminal unit is covalently bonded to the backbone moiety of one other unit, and 3) the backbone moiety of each intermediate unit is covalently bonded to the backbone moieties of two other units; and B) a series of units comprising a divalent nucleobase covalently bonded to the backbone moiety; and b) two aryl moieties, one covalently bonded to the first unit and one covalently bonded to the terminal unit.

[0091] In some embodiments, the disclosure provides compounds in which a first aryl moiety is covalently linked to a first unit by a first linker moiety and a final aryl moiety is covalently linked to a final unit by a final linker moiety. In some embodiments, the disclosure provides compounds in which the first linker moiety and the final linker moiety each independently comprise a guanidine group. In some embodiments, the disclosure provides compounds in which the first linker moiety and the final linker moiety each independently comprise an amino acid residue. In some embodiments, the disclosure provides compounds in which the first linker moiety and the final linker moiety each independently comprise three guanidine-containing amino acid residues.

[0092] In some embodiments, the disclosure provides compounds where the first linker moiety and the final linker moiety each independently comprise three adjacent arginine residues. In some embodiments, the disclosure provides compounds where the series of units is 3-8 units. In some embodiments, the disclosure provides compounds where the series of units is γ-PNA. In some embodiments, the disclosure provides compounds where the first aryl moiety and the final aryl moiety each independently are 2-5 ring fused polycyclic aromatic moieties, e.g., polyaromatic hydrocarbons, e.g., pyrene. In some embodiments, the disclosure provides compounds where the first aryl moiety and the final aryl moiety are identical. In some embodiments, the disclosure provides compounds further comprising an ethylene glycol unit, e.g., a diethylene glycol unit.

[0093] In some embodiments, the disclosure provides compounds that present bivalent nucleobases in a complementary order to a target nucleic acid sequence. In some embodiments, the disclosure provides compounds where the target nucleic acid sequence is associated with a repeat expansion disease. In some embodiments, the disclosure provides compounds where the repeat expansion disease is myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2). In some embodiments, the disclosure provides compounds where the first aryl moiety of one compound stacks with the final aryl moiety of the other compound when the two compounds hybridize with a nucleic acid.

[0094] In some embodiments, the disclosure provides a compound of the formula: L Arg-CAGCAG- L Arg-NH2(P1), H- L Arg- L Dab(Pyr)-CAGCAG- L Orn (Pyr) - L Arg-NH2(P2), H- L Arg- L Orn(Pyr)-CAGCAG- L Orn (Pyr) - L Arg-NH2(P3), H- L Arg- L Lys(Pyr)-CAGCAG- L Lys(Pyr)- L Arg-NH2(P4), H- L Arg- L Lys(Pyr)-CATCAG- L Lys(Pyr)- L Arg-NH2(P5), or H- L Arg- L Lys(Pyr)-CTGCTG- L Lys(Pyr)- LThe compound Arg-NH2(P6) is provided, where Orn is ornithine, Dab is diaminobutyric acid, and Pyr is a carboxyl-functionalized aromatic compound, e.g., pyrene, such as pyrene-1-carboxylic acid, pyrene-2-carboxylic acid, pyrene-4-carboxylic acid, pyrene-1-acetic acid, pyrene-2-acetic acid, or pyrene-4-acetic acid.

[0095] In some embodiments, the disclosure provides a method of binding a nucleic acid, the method comprising contacting the nucleic acid with a disclosed compound, where the compound binds to the nucleic acid upon contact. In some embodiments, the disclosure provides a method of knocking down expression of an mRNA in a cell, the method comprising contacting the cell with a disclosed compound, where the compound knocks down expression of the mRNA in the cell upon binding to a DNA sequence in the cell that corresponds to the mRNA.

[0096] In some embodiments, the disclosure provides a genetic recognition reagent that includes a nucleic acid or nucleic acid analog backbone having a first end and a second end and having from 3 to 8 ribose-5-phosphate, deoxyribose-5-phosphate, or nucleic acid analog backbone residues, a bivalent nucleobase, which may be the same or different, linked to a plurality of ribose-5-phosphate, deoxyribose-5-phosphate, or nucleic acid analog backbone residues, a first aryl moiety linked to the first end of the nucleic acid or nucleic acid analog backbone by a linker, and a second aryl moiety, which may optionally be the same as the first aryl moiety, linked to the second end of the nucleic acid or nucleic acid analog backbone by a linker.

[0097] In some embodiments, the disclosure provides a detection method comprising: a) hybridizing a first probe nucleic acid comprising one or more divalent nucleobases, a first end connected to a first emitter moiety, and a second end connected to a second emitter moiety, to a first repeat portion of a target nucleic acid; and b) hybridizing a second probe nucleic acid comprising one or more divalent nucleobases, a first end connected to a third emitter moiety, and a second end connected to a fourth emitter moiety, to a second repeat portion of the target nucleic acid, wherein i) the first and second repeat portions of the target nucleic acid are associated with a repeat expansion disorder, ii) binding of the first probe nucleic acid and the second probe nucleic acid to the target results in the first or second emitter moiety in close proximity to the third or fourth emitter moiety, and iii) the presence of the first or second emitter moiety in close proximity to the third or fourth emitter moiety causes a change in the emission wavelength of the emitter moiety in close proximity.

[0098] In some embodiments, the detection method further comprises detecting a change in the emission wavelength of the emitter moieties in close proximity. In some embodiments, hybridization of the first probe nucleic acid to the first repeat portion increases the affinity of the second probe nucleic acid for the second repeat portion. In some embodiments, the presence of the first or second emitter moiety in close proximity to the third or fourth emitter moiety causes a π-π stacking interaction between the first or second emitter moiety and the third or fourth emitter moiety. In some embodiments, the target nucleic acid is obtained directly from a biological sample. EXAMPLES

[0099] Example 1 NMR, X-ray, and biochemical studies revealed that the rCAG-hairpin structure is relatively dynamic compared to the canonical RNA duplex, with the AA internal ridges exhibiting large amplitude motion. Such molecular scaffolds, containing internal AA mismatches at all two canonical GC / CG base pairs (Figure 1(A)), similar to "holes" in the road, provide distinct viable receptor-like binding sites for exogenous ligands. Relatively short nucleic acid ligands targeting the rCAG-hairpin structure were developed (Figure 1(B)). Janus bases (J bases, i.e., JB), E, ​​I, and F (Figure 1(C)), were used, which can form divalent H-bond interactions with nucleic acid bases in both strands of the RNA duplex with a conformationally preorganized MPyPNA backbone (Figure 1(D and E)). The J bases described herein are part of a larger set of double-sided nucleic acid recognition elements, 16 in total, designed to bind all 16 possible RNA base pair combinations (Figures 5A-5C). They differ from other J bases, including "Janus-wedges," in that they are uniform in shape, size, and chemical functionality and, therefore, combined with a modular format, can recognize any combination of RNA base pairs.

[0100] Molecular dynamics (MD) simulation To evaluate the viability of the bivalent recognition design concept, MD simulations of ligand LG1 bound to an RNA duplex containing four rCAG repeats were performed. The C-terminal lysine residue was omitted and the MP side chain was replaced with a methyl group (MeγPNA) to simplify computational modeling. CEO, AIA, and GFC triads were constructed, optimized with the 6-31 basis set, and grafted onto each RNA and MeγPNA backbone. The structure of the bound RNA-LGl-RNA complex was created using the NAB module of Ambertool. The final structure was solvated with water molecules and ions, energy minimized, and simulated for 100 ns. The resulting complex remained fairly stable throughout the simulation, with the four distinct LG1 ligands fitting snugly between the two RNA strands (Figure 6(A)). The number of H-bonds, five for each of the CEO and GFC triads and four for AIA (Figure 6(B)), remained unchanged during the simulation (Figure 6(C)). However, attempts to simulate binding with fewer than four LG1 ligands were unsuccessful: the complex unraveled and formed a distorted structure, in part due to instability of the terminal base pairs ( Fig. 6 (D and E) ).

[0101] Synthesis of Chemical Building Blocks and Ligands J bases E and F were synthesized along with the corresponding JB-MPγPNA monomers 1-3 (Figure 7). J base I was not prepared as it is commercially available. E and F were synthesized according to Scheme 1 (Figure 8) and Scheme 2 (Figure 9), respectively. The Boc protection / deprotection sequence in compounds 5-9 was found to be favorable for improving the chemical yield of the NBS reaction and suppressing side reactions in the subsequent condensation and cyclization steps. Further protection of 12 was found to be favorable for the smooth proceeding of the Stille coupling. This was achieved using Boc anhydride and carried out at elevated temperatures. Despite the apparent bulkiness, there were no problems in coupling E to the MPγPNA backbone or in the assembly of the corresponding monomer on the MBHA resin. The core structure of F, 4-amino-2-(methylthio)pyridine-5-carbonitrile (17), was prepared according to published protocols. Subsequent conversion of the cyano group to the amidine followed by Boc protection afforded 21. Attempts to completely protect the exocyclic amine with a large excess of Boc anhydride under various conditions were unsuccessful, as this led to the formation of multiple spots on TLC with different numbers of Boc groups that were difficult to separate by column chromatography. To address this challenge, a two-step Boc protection was performed. 22 was subjected to oxidation and hydrolysis, followed by alkylation and hydrogenolysis to give F. Once prepared, E (15), F (26), and I (27) were coupled to the MPγPNA backbone (Figure 10, Scheme 3). Removal of the Alloc protecting groups afforded the desired monomers 1–3. Ligands LG1, LG2, and LG3, along with LG2P, which is in the opposite (parallel) orientation to LG2, were prepared on MBHA resin using the PAL linker and HBTU as coupling reagents. LG2P was included as a negative control, as the parent LG2 ligand showed the highest promise for binding rCAG repeats. A lysine residue was incorporated at the C-terminus to improve aqueous solubility. Upon completion of the final monomer coupling, the ligand was cleaved from the resin, precipitated with diethyl ether, purified by RP-HPLC, and confirmed by MALDI-TOF mass spectrometry (Table D).

[0102] [Table D] [ka]

[0103] Target selection and sample preparation A series of model RNA targets were selected for binding studies (Figure 11). The R11X series contained 24 rCXG repeats (Figure 11(A)), which, when adopted as a secondary hairpin structure, provided 11 binding sites for ligands (Figure 11(B)). R11A contained a perfect match (AA), while R11U and R11C contained mismatches of the ligand binding UU and CC, respectively. R11G (X=G) was not examined because it has been shown to form G-quadruplexes as well as hairpin structures, which may confound the interpretation of the experimental results. The single-stranded RNA targets WS (Watson strand) and CS (Crick strand) (Figure 11(C)), with the LG2 binding site underlined, and the double-stranded hairpin HP (Figure 11(D)), which contains a single ligand binding site, were also examined. Samples were prepared by incubating preannealed RNA with each ligand in 0.1x PBS buffer (1 mM NaPi, 13.7 mM NaCl, 0.27 mM KCl, pH 7.4) at 37° C. This particular buffer was chosen based on our initial screens, in which we found that R11A adopts a stable hairpin structure and that the ligand can bind.

[0104] Spectroscopic identification of ligand binding A combination of UV-Vis and circular dichroism (CD) was used to determine the binding properties of the ligands. UV-Vis measurements revealed that all three ligands can bind to R11A. Evidence for their interaction can be gathered from the hypochromic effect and bathochromic shift in the absorption of [R11A + ligand] at 252 and 330 nm. The UV absorption in the 275-375 nm regime corresponds to the π-π* transition of the E base. This finding was supported by the CD data revealing a significant increase and red shift in the signal around 270 nm. Of this series, LG2 showed the greatest difference in CD amplitude. CD titration of LG2 with R11A reached a saturation point at an 11:1 ratio, which is consistent with the predicted number of ligand binding sites for R11A (Figure 12). We hypothesized that R11A adopts a uniform hairpin structure because it is thermally annealed prior to the addition of the ligand, however, other combinations of intra- and intermolecular folding are possible. In contrast, no significant differences were observed in the CD signal after incubation of LG2 mismatches R11U (Figure 13(A)) and R11C (data not shown), single-stranded WS and CS (Figure 13(B)), double-stranded HP containing a single binding site (Figure 13(C)), or mismatched orientation LG2P with R11A (Figure 13(D)). The results for the R11U and R11C mismatches were nearly identical in every respect, so all further discussion of base mismatches will focus on R11U. Taken together, these results indicate that the interaction between ligand and RNA occurs in a sequence- and orientation-specific manner, with a preference for double-stranded over single-stranded RNA targets and an advantage for those with multiple contiguous binding sites over isolated ones.

[0105] Confirmation of ligand binding by fluorescence measurement To further substantiate the UV-Vis and CD findings, the fluorescence signals of the ligands were measured in the presence and absence of the RNA target after excitation at 330 nm (λmax of the E base). Significant fluorescence quenching of LG3 was observed compared to LG1 and LG2. Such a dramatic decrease in fluorescence signal could be due to photoinduced electron transfer quenching, which is expected to be most efficient for LG3 since the fluorophore (E) is stacked between two other J bases. This interpretation is consistent with the observation that the fluorescence signal of LG3 is fully restored by heating (data not shown). For all three ligands, the emission signal was further decreased by the addition of R11A, but most dramatically for LG2, with a 60% decrease for LG2 compared to 35 and 33% for LG1 and LG3, respectively. Similar fluorescence quenching patterns were observed upon incubation of LG2 with R11U, [WS+CS], HP, and LG2P with R11A (Figure 14), although less dramatic than that of LG2 with R11A. Similar observations were made with a related class of bicyclic pyrimidine analogues, indicating that the fluorescence yield of these fused-ring fluorophores is highly sensitive to the local environment. To test the hypothesis that nonspecific binding of the ligand to RNA could lead to fluorescence quenching, each RNA target was incubated with pentamidine followed by the addition of LG2 and vice versa. Data showed that the fluorescence signals of LG2 with R11U and [WS+CS], as well as those of LG2P with R11A, were fully restored, except in the case of LG2 with R11A (Figure 14, inset), which remained suppressed. This result is consistent with LG2 binding to R11A by a mode different from that of pentamidine, presumably via a defined divalent H-bonding interaction (Fig. 1B and C).

[0106] NMR titration To gain insight into the binding mode of LG2, a series of multinuclear and multidimensional NMR experiments were performed with LG2, R11A, and in combination. Samples were prepared in 0.1× PBS buffer, identical to previous ones, containing a 9:1 volume ratio of H2O:D2O. NOESY data were collected with mixing times of 300, 200, and 100 ms to obtain interproton distances, while COSY experiments were performed to map the proton spin system of each residue. The H-bond interaction between LG2 and R11A was expected to result in line broadening and downfield chemical shifts of the imino proton signals of the canonical GC / CG pair due to base pair opening, and the appearance of a new set of imino proton signals due to the formation of H-bonds between the ligand and RNA. In agreement with the CD data, 1 H-NMR experiments revealed that R11A adopts a stable hairpin structure in 0.1× PBS buffer as evidenced by a sharp imino proton signal at 12.35 ppm. Variable temperature measurements further supported this chemical shift assignment, showing that the peak intensity gradually attenuated with increasing temperature, while the peak intensity of the non-exchangeable protons remained almost constant. Partial assignment of the nucleobase protons was performed by NOESY experiments. As expected, the imino proton signals of R11A were gradually broadened and downfield shifted with the addition of LG2 (Figure 15). Furthermore, the chemical shifts of C4-NH and G2-NH were significantly affected, indicating their interaction with the ligand. Despite our efforts, the degeneracy in the repeat sequence prevented us from assigning and thus monitoring the chemical shift of A6-NH upon titration of LG2 against R11A. Nevertheless, the results indicate that GC / CG base pair opening is mediated by the ligand. However, we did not observe any new imino proton signals in the 10-20 ppm regime, as would be expected for H-bond formation between the ligand and RNA.

[0107] Template-Mediated Native Chemical Ligation (NCL) Weak and transient interactions of the ligand with RNA, as observed for LG2 and R11A, are unlikely to result in significant biological responses. To further improve the binding affinity of LG2, a second LG2 derivative, LG2N (Figure 16(A)), was synthesized, which contained a C-terminal thioester and an N-terminal cystine. This ligand was prepared using a second generation N-acylurea linker. The dual-functional probe design takes advantage of the conformational preorganization of MPγPNA in preventing the two functional groups from spontaneously reacting with each other upon reduction of the disulfide bond. The cystine group was used to better control probe handling. Previous studies have revealed that ligands of the same length containing all natural nucleobases have a reduced (acyclic) half-life of approximately 1 hour at physiological temperature (37°C). A similar half-life was expected for LG2N*. Figure 16(B) shows the reaction pathway of LG2N after reduction of the disulfide bond, the predicted chemical state of LG2N in a reducing intracellular environment. In the presence of the RNA target, the ligand was predicted to form transient divalent H-bond interactions with the nucleobases of the neighboring RNA target as a result of intermolecular base stacking (step 2). Upon cleavage of the disulfide bond, the ligand undergoes template-mediated NCL to form a linked product that more tightly binds the RNA template (step 3). In the absence of the RNA target, the ligand self-inactivates by undergoing an intramolecular NCL reaction to form a cyclic product (step 4).

[0108] To confirm the expectation that LG2N would remain stable for a period of time after reduction of the disulfide bond before undergoing cyclization, *The reaction progress of parent compound M, in which M is induced in situ, was monitored (Figure 17(A)). For quantification of the reaction products, MALDI-TOF was chosen over HPLC and other analytical techniques because intramolecular NCL has a relatively short timescale and can be achieved in less than 5 min using the former. We attempted to quench the reaction with an electrophile prior to HPLC analysis, however, such efforts were unsuccessful due to the rapid intramolecular reaction of the ligand. 4-mercaptophenol (4MP) and 2-mercaptoethanol (2ME) were investigated as possible reducing agents. Both yielded similar kinetic profiles for parent compound M, however, the former resulted in intermediates with mass-to-charge ratios (m / z) overlapping with the hydrolyzed parent compound, making them difficult to differentiate from each other. For this reason, 4MP was chosen for reaction monitoring by MALDI-TOF and gel shift assays, whereas 2ME was used for subsequent melting experiments due to its transparency in the nucleobase absorption region. Our data reveal that the addition of 4MP to the parent compound M initially led to the formation of two reactive species corresponding to transesterification (M#) and C-terminal thioester (M##) (Figure 17(A)). These persisted for <15 min before disappearing as reactive LG2N * It was converted to an intermediate and finally to a cyclic product (cLG2N) (Figure 17(B)). * was stable at physiological temperatures. It was present as the major product at 1 h of reduction and constituted approximately 75% of the total products in the mixture, with the remaining 25% being primarily cLG2N. * has a half-life of approximately 3 hours, nearly three times longer than its natural counterpart. * We attribute the chemical stability of to the enlarged aromatic ring size of the E base, which provides better base stacking interactions and therefore makes the ligand less conformationally flexible.

[0109] Next, UV melting experiments were performed to determine the effect of template-mediated NCL on RNA thermal stability. Samples were prepared in 0.1× PBS buffer at a ratio of 2:1 for LG2N to the number of binding sites for R11A and incubated at 37°C for 16 h before UV melting analysis. As expected, in the absence of reducing agent, LG2N was able to inhibit the melting transition (T m ) with a maximum effect of about +1°C ΔT m The same was observed for LG2, which does not contain a C-terminal thioester or an N-terminal cysteine. However, the results were similar whether the incubation of [LG2N+R11A] was performed at ambient temperature or at 37°C in the presence of 2ME. m A significant increase in T was observed in the range of 59–68 °C in both cases. The derivatives of the melting curves showed a broad sigmoidal distribution, suggesting the presence of various ligation products formed and bound to the RNA template. This finding was expected for template-mediated synthesis. m Despite their similarity, the two melting curves differ in pattern, with the one incubated at higher temperature showing reversed light absorption in the 25-50 °C range. This melting behavior is characteristic of hydrophobic / aromatic interactions, a phenomenon previously observed in thermophilic foldamers and other aromatic systems, such as perylenes and pyrenes. We attributed the reversed intensity distribution to interactions of the J bases of the ligated products, which were probably formed in greater amounts at 37 °C than at ambient temperature. Upon heating, the hydrophobic interactions became more pronounced up to a certain point (approximately 50 °C), beyond which repulsion occurred. The enhanced thermal stability of R11A is consistent with the formation of NCL products and their binding to the RNA template.

[0110] R11A T mTo confirm that the enhancement in is due to template-mediated ligation and binding of the resulting products to the RNA template, MALDI-TOF analysis was performed on UV-melted samples followed by heating. The formation of ligated products is evident from the appearance of new peaks with gradually increasing m / z values ​​with a step size of approximately 1319 Daltons, according to the mass of the ligand (Figure 18(A)). However, these ligated products were not observed with the mismatch R11U (Figure 18(B)) or with LG2N alone without target (Figure 18(C)). Similarly, there was no evidence of ligated products being formed with single-stranded [WS+CS] or double-stranded HP (data not shown). This result is consistent with the occurrence of template-mediated synthesis mediated by the R11A hairpin structure.

[0111] Selective binding of tethered ligands LG2N is rCAG exp Competitive binding assays were performed to determine whether r(CAG) repeats in the normal (R24A, n = 24, identical to R11A) and pathogenic (R127A, n = 127) ranges could be distinguished from normal repeats. n Mismatch repeat r(CUG) 96Two RNA targets were used, including one with a control (R96U). Employing each hairpin motif, these RNA transcripts provide 11, 62, and 47 binding sites for LG2N. Two sets of samples were prepared, one in 0.1x PBS and the other in a physiologically relevant buffer (10 mM NaPi, 150 mM KCl, 2 mM MgCl2, pH 7.4). In both sets, equimolar mixtures of R24A (100 nM chain concentration, 1.1 μM binding sites) and R127A (18 nM chain concentration, 1.1 μM binding sites) were incubated with various concentrations of LG2N, 4MP, and TCEP for 24 h at 37°C. TCEP was included to ensure that disulfide bonds were completely reduced. The reaction mixtures were analyzed by agarose gel and stained with SYBR-Gold for visualization. Inspection of Figure 19 reveals that LG2N binds preferentially to R127A over R24A, as evidenced by the faster rate of disappearance of the top two bands compared to the bottom band in lanes 2-5. Such binding events occurred only in the presence of reducing agents and with perfectly matched RNA targets, since no evidence of binding was observed in the absence of 4MP and TCEP (compare lane 6 with lane 1) and with the mismatch R96U (compare lane 8 with lane 7). No shifted bands were observed to form, as would be expected for ligand-RNA complexation. This suggests that SYBR Gold was unable to intercalate the RNA-ligand complex, an observation that was not surprising given that ligand binding is known to induce dramatic changes in RNA conformation (Figure 6). In contrast, no evidence of ligand binding occurring at physiologically relevant ionic strength was observed (Figure 20), implying that under such conditions, the RNA hairpin was unable to mediate template-mediated ligand oligomerization.

[0112] Many neuromuscular disorders, including HD, myotonic dystrophy types 1 (DM1) and 2 (DM2), spinocerebellar ataxia (SCA), fragile X syndrome (FXS), Friedreich's ataxia (FRDA), and subpopulations of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), manifest as a result of unstable repeat expansions. Expansions in the coding regions of genes can lead to alterations in protein function, while expansions occurring in non-coding regions can cause disease that does not interfere with the protein sequence and / or the unintended production of harmful polypeptides by RNA translation due to toxic gain of RNA function. Many of these genetic disorders are autosomal dominant, requiring an expansion (or mutation) in only one allele to cause disease. Thus, one way to interfere with such disease pathways is to target the affected allele or the corresponding gene transcript. Between the two, the latter offers greater accessibility to exogenous molecules and greater recognition specificity for bivalent ligands, such as JB-MPyPNA, due to its propensity to adopt imperfect hairpin structures.

[0113] We focused our efforts on rCAG repeats because of their expansive genetic penetrance in HD and other neurodegenerative disorders, including but not limited to MJD, SBMA, DRPLA, and SCA. Molecules that selectively bind mutant htt transcripts and interfere with disease pathways can be used to treat HD as well as other related genetic disorders. The nucleic acid ligands described herein differ from conventional antisense drugs in several ways. First, they bind to CAG-RNA hairpin motifs through bivalent H-bond interactions. Second, they are relatively small in size, the length of a single triplet repeat unit. Thus, they are easier to chemically synthesize, structurally modify, and scale up by solution-phase chemistry rather than solid-phase chemistry. Third, for molecular weights on the outer edge of small molecules, such "miramolecule" systems generally have more favorable pharmacokinetic properties than typical antisense drugs. Fourth, J-base recognition is more sequence-specific and selective. A single base mismatch that normally occurs on one side of a natural nucleobase occurs on both sides of a J base, making it more specific and more selective, favoring double-stranded over single-stranded RNA targets due to the large difference in binding free energy of the two resulting products. However, unlike small molecules, or riboswitches, the recognition of J bases follows a set of predefined rules, with bivalent Watson-Crick H-bond interactions rather than a more diverse combination of attractive forces. Furthermore, the JB-ligand design is modular. Thus, ligands can be prepared and modified to bind any sequence of RNA repeats. This allows further improvement of recognition selectivity by tuning the binding affinity of the ligand and by adjusting the ionic strength of the buffer, so a weak and transient interaction of the JB-ligand with normal-length rCAG repeats at low salt concentrations is desirable at the initial design stage.

[0114] material and method UV melt analysis All UV melting samples were prepared by mixing the ligand with the RNA target at the indicated concentrations in 0.1× PBS buffer and annealed by incubation at 90°C for 5 min, followed by gradual cooling to room temperature. UV melting curves were collected using an Agilent Cary UV-Vis300 spectrometer equipped with a thermoelectrically controlled multicell holder. UV melting spectra were collected by monitoring UV absorption at 260 nm from 25°C to 95°C for heating experiments and from 95°C to 25°C for cooling experiments, both at a rate of 1°C per minute. The cooling and heating curves were nearly identical, implying that the hybridization process was reversible. The recorded spectra were smoothed using a 20-point adjacent averaging algorithm. The first derivative of the melting curve was utilized to determine the melting temperature of the complex.

[0115] CD analysis Samples were prepared in 0.1x PBS buffer. All spectra represent the average of at least 15 scans collected at 25°C in a 1 cm path length cuvette between 200 and 375 nm at a rate of 100 nm / min. The CD spectra from the buffer solutions were subtracted from the sample spectra, which were then smoothed by a 5-point adjacent average algorithm. Steady-state fluorescence measurements. All steady-state fluorescence samples were prepared by mixing the ligand with the RNA in 0.1x PBS buffer at the indicated concentrations and annealed by incubation at 90°C for 5 min, followed by gradual cooling to 37°C. Samples were incubated at 37°C for 1 h before measurements. Steady-state fluorescence data were collected at 25°C on a Cary Eclipse Fluorescence spectrometer. (ε ex = 330 nm, ε em =340~600nm).

[0116] Competitive binding assays R24A was purchased from IDT. R127A [r(CAG) 127 ] and R96U[r(CUG)96

[0111] were prepared as previously described. R24A, R126A, and R96U were prepared in 0.1x PBS buffer and annealed by heating at 90°C for 5 min, followed by slow cooling to room temperature. Ligands and RNA were mixed at the indicated concentrations and incubated at 37°C for 24 h. Samples were then loaded onto a 2% agarose gel with 1x Tris-borate buffer and separated by electrophoresis at 100V for 25 min. Gels were stained with SYBR-Gold and visualized with a UV-Transilluminator.

[0117] MD simulation, ligand synthesis, and monomer synthesis The procedures are presented in the accompanying Supplementary Information, which is incorporated herein.

[0118] general technology All starting materials and chemicals were purchased from commercial suppliers and used without further purification unless otherwise stated. All reactions were carried out under anhydrous conditions with dry solvents under nitrogen atmosphere unless otherwise stated. Removal of solvent in vacuum refers to distillation using a rotary evaporator attached to a high vacuum pump. Products obtained as solids, syrups, or liquids were dried under high vacuum. Analytical thin-layer chromatography was performed on precoated silica plates (60F-254, 0.25 mm thickness) and compounds were visualized by UV light or by staining with ninhydrin or iodine, or heat as a development means. NMR spectra were recorded at either 300 or 500 MHz using CDCl3, DMSO, and D2O as solvents and TMS as an internal standard. The following abbreviations were used to describe the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, ddt = triplet doublet doublet, dt = triplet doublet, td = doublet triplet, ABq = AB quartet, dd = doublet doublet, tt = triplet triplet, br = broad wtc. High-resolution mass spectrometry (HRMS) was performed using an ESI-ESI-TOF mass analyzer and a DART analyzer. Low-resolution mass spectrometry (LRMS) was performed using an ESI-Ion Trap-MS mass analyzer. Unless otherwise stated, for oligomer purification on RP-HPLC a C18 (15 cm x 2.1 mm, 5 μm particles) column was used with a linear elution gradient (Method A) from 95% HO (0.01% TFA) in 40 min to 95% MeCN (0.01% TFA) at a flow rate of 1.0 mL / min. MALDI spectra were measured using a TOF / TOF spectrometer. Absorption profiles were recorded on a UV-Vis spectrophotometer. Circular dichroism (CD) spectra were recorded on a Spectropolarimeter. Fluorescence (emission) was recorded on a Fluorescence Spectrophotometer.

[0119] MD simulation The C-terminal lysine residue was omitted from γPNA and the MP side chain was replaced with a methyl group (MeγPNA, published X-ray crystal structure, PDB-ID3PA0). The CEG, AIA, and GFC triads were constructed using Chimera 1 and the HF / 6-31G set with a Gaussian distribution. * The helical structure of the bound RNA-HD1-RNA complex was created from the triad using the NAB module of Ambertool, and a modified MeγPNA scaffold from the crystal structure was grafted onto the helical structure (initial structure, as shown in Figure 2A). Four such RNA-HD1-RNA complexes were obtained, in which the RNA was a duplex containing four rCAG repeats, and the number of HD1 ligands bound to the RNA varied from one to four. For each RNA-(HDl) n The -RNA complex was solvated with TIP3P4 water molecules and ions were added to neutralize the charges. The system was energy minimized and then heated to 300 K under harmonic restraints of 25 Kcal / mol / Å on the atoms of the RNA and HD1 ligand. The restraints were gradually released in a series of six short simulations, and finally an unrestrained NPT simulation was performed at 300 K and 1 bar pressure for 100 ns using a Nose-Hoover thermostat and a Parinello-Rahman barostat, respectively. Electrostatic interactions were treated using the particle mesh Ewald method, and all simulations were performed using the GROMACS Amber99-parmbsc0 force field with χOL3 modification for the RNA, and the general amber force field was used to generate the force field parameters for the HD1 ligand.

[0120] Resin loading [(MP)(PAL)]

[0121] (1)MP loading. 1 g of MBHA resin (1 mmol / g, Peptide International, RMB-2100-PI) was soaked in DCM in a reaction vessel for 1 hour, then washed with DCM (3x) and 5% DIEA in DCM (3x). See Figure 21. Once the Kaiser test confirmed that the amine groups were neutralized (blue), the following solutions were added sequentially to a 15 mL canonical tube: 3.5 mL of NMP, 450 μL of solution A, 460 μL of solution B, and 550 μL of solution C. The mixture was vortexed for 10 seconds and allowed to sit for 3 minutes before being added to the resin in the reaction vessel. The reaction was allowed to proceed for 1 hour with gentle shaking. The reaction mixture was emptied with positive air pressure, and the resin was washed with DMF (3x), DCM (3x), 5% DIEA in DCM (1x), and DCM (3X). The resin was capped by adding capping solution to the reaction vessel and gently agitating the vessel for 45 minutes (2X). After discarding the final capping solution, the resin was washed with DCM (3X) and complete capping was confirmed by Kaiser test (light yellow color).

[0122] Solution A: 43 mg of Fmoc-MP (0.200 M) in 500 μL of NMP Solution B: 87 μL DIEA (0.500 M) in 913 μL pyridine Solution C: 55 mg of HATU (0.201 M) in 750 μL of NMP Capping solution (Ac2O / NMP / pyridine: 112 / 2): 2 mL Ac2O, 4 mL NMP, and 4 mL pyridine

[0123] (2) Loading of PAL and Lys (1 g of resin from the previous section). The Fmoc protecting group was removed by treating the resin with 20% piperidine in DMF solution (2x) for 7 min each, followed by washing with DMF (3x) and DCM (3x). Once successful removal of Fmoc was confirmed by Kaiser test (blue color), the coupling solution was prepared by mixing the following materials: 3 mL of 0.2 M monomer solution, 1.5 mL of 0.52 M DIEA solution, and 1.5 mL of 0.39 M HBTU solution. The mixture was activated for 3 min and then added to the resin. The reaction was allowed to proceed for 30 min with gentle agitation of the reaction vessel. Completion of the reaction was confirmed by Kaiser test (light yellow color). The resin was washed with DMF (3x), 5% DIEA solution (1x), and DCM (1x), and unreacted amines were capped by adding capping solution to the resin and gentle agitation of the reaction vessel for 30 min. After removing the capping solution, the resin was washed with 20% piperidine (2x), DMF (2x), and DCM (2x).

[0124] Monomer solution: 303 mg of Fmoc-PAL (0.200 M) in 3 mL of NMP 281 mg of Fmoc-Lys(Boc)-OH (0.200 M) in 3 mL of NMP DIEA solution: 364 μL DIEA (0.52 M) in 3.638 mL DMF HBTU solution: 740 mg HBTU (0.39 M) in 5 mL DMF Capping solution: (Ac2O / NMP / pyridine: 1 / 25 / 25vol)

[0125] Fmoc deprotection The Fmoc protecting group was removed by treating the resin with a solution of 20% piperidine in DMF (0.5 mL for 50 mg resin) (2x) for 7 min each, followed by washing with DMF (3x) and DCM (3x). Fmoc deprotection was confirmed by the Kaiser test (blue color).

[0126] Monomer Coupling Once the Fmoc was successfully removed by the Kaiser test (blue color), the resin was washed with DMF (4x) and DCM (5x). The coupling solution was prepared by mixing the following materials: 150 μL of 0.2 M monomer solution, 75 μL of 0.52 M DIEA solution, and 75 μL of 0.39 M HBTU solution. The mixture was activated for 10 min. After washing the resin with pyridine (1x), the monomer solution was added to the resin. The reaction was allowed to proceed for 2-4 hours with gentle agitation of the reaction vessel. Completion of the reaction was confirmed by Kaiser test (light yellow color). The resin was washed with DMF (3x) and DCM (3x).

[0127] Capping. Unreacted amines were capped with freshly prepared capping solution: Capping solution (1:25:25, acetic anhydride:NMP:Py) was added to the resin and the reaction vessel was agitated for 4 min. The resin was washed with DMF (4x) and DCM (5x).

[0128] Disconnect After the final Fmoc deprotection step, the resin was washed with DMF (5x) and DCM (8x). The resin was dried under vacuum for 15 min. To the dried resin, freshly prepared 95% TFA:5% m-cresol (0.6 mL for 50 mg resin) was added and the reaction vessel was kept in standby mode. After 1 h at room temperature, the TFA solution was collected in a canonical centrifuge tube. Again, the cleavage solution (0.5 mL for 50 mg resin) was added to the resin and the reaction vessel was allowed to stand for 30 min. The TFA solution was combined with the previously collected solution.

[0129] Precipitation To the combined TFA solutions was added cold, dry diethyl ether (-60°C, 14 mL) and shaken. Precipitation occurred within 30 min. The precipitated oligomers were collected by centrifugation and washed with cold diethyl ether (2x).

[0130] purification The crude oligomer was dissolved in 0.5 mL of 95% water, 5% acetonitrile, and 0.1% TFA. The resulting solution was purified by reverse phase analytical column.

[0131] Example 2 - Monomer synthesis

[0132] [ka]

[0133] Monomer E(1) Palladium tetrakis(triphenylphosphine) (28.22 mg, 24.42 μmol) was added to a mixture of phenylsilane (0.12 mL, 0.98 mmol) and allylic monomer 29a (0.60 g, 0.49 mmol) in anhydrous dichloromethane (10 mL) at room temperature. Complete conversion of the starting material to the corresponding acid was observed by TLC over 15 h (eluent: EA:Hex(SO:SO), Rf 0.6 for 29a, Rf = 0.0 for product (dragging)). Silica gel was added to the reaction mixture at room temperature and the solvent was removed on a rotary evaporator. The silica gel adsorbed crude product was purified by flash silica gel chromatography to give the desired product. Yield: 0.44 g, 7 S%. 1 H NMR (S00.13 MHz, DMSO-d6, rotamer): δ 1.08 / 1.09(s / s,9H),1.25-1.28(m,18H),1.37-1.38(m,18H),1.41 / 1.6S(s / s,9H),3.12-3.64(m,13H),3.77-3.90(m,2H), 3.90-4.00(m,2H),3.99-4.4.34(m,4H),7.21-7.49(m,5H),7.54-7.79(m,2H),7.89(d,J=7.2 Hz,2H),8.55 / 8.64(s / s,1H), 13C NMR (125.77 MHz, DMSO-d6, rotamer): δ 27.2-27.6(18C,tBu),35.8,46.7,54.9,59.7,60.6 / 60.6(2C),65.6 / 65.6,69.6 / 69 .6,69.8 / 69.9,70.4 / 70.4,72.2 / 72.2,82.1(3C),82.2,83.2,83.4,86.2,108.1,12 0.1(2C),125.2,127.0(4C),127.6(4C),140.7(2C),143.8 / 143.8,147.9,149.2 / 14 9.3,149.3,149.5,149.7,155.0 / 155.9,156.3 / 156.5,162.3,166.6 / 166.6,HRMS:[C 61 H 85 N7O 17 +H] calculated m / z: 1188.6080, found: 1188.6071.

[0134] [ka]

[0135] Monomer I(2) This compound was prepared using the procedure described above for compound 1, starting from compound 29b (3.10 g, 4.39 mmol) as starting material. TLC (eluent: MeOH:DCM (5.95), Rr for 29b = 0.2, Rf for 2 = 0.0). Yield: 2.22 g, 76%. 1 H NMR(300.13 MHz,DMSO-d6):δ 1.09(bs,9H),3.11-3.52(m,15H),3.87-3.96(m,2H),4.24(dd,J=13.4,5.4 Hz,4H),7.19-7.44(m,SH),7.69(d,J=7.5 Hz,2H),7.89(d,J=7.4 Hz,2H),10.71-10.75(m,1H),11.06(bs,1H),12.46(bs,1H), 13C NMR (126 MHz, DMSO-d6, rotamer): δ 27.8(3C),47.2 / 47.2,61.1(3C),65.6 / 66.0,70.1(2C),70.3 / 70.4,70.9(3C),72.7,107.8 ,120.6-128.1(10C),139.7 / 140.1,141.2(2C),144.3,151.8,156.3,164.6,170.9,HRMS:[C 34 H 42 N4O 10 +H] calculated m / z: 667.2979, found: 667.2988.

[0136] [ka]

[0137] Monomer F(3) This compound was prepared using the procedure described above for compound 1, starting from compound 29c (2.50 g, 2.00 mmol) as starting material. TLC (eluent: EA:Hex (50:50), 29c Rf=0.6, 3 Rf=0.0 (dragging)). Yield: 1.94 g, 80%. 1 H NMR (300.13 MHz, DMSO-d6, rotamer): δ 1.08(s,9H),1.35(s,9H),1.36(s,9H),1.41 / 1.42(s / s,18H),3.20-3.62(m,20H),3.7 7-4.15(m,4H),4.18-4.34(m,4H),4.82-5.35(m,2H),7.17-7.46(m,5H),7.70(d,J=7.0 Hz,2H),7.88(d,J=7.5 Hz,2H),8.93 / 8.95(s / s,1H), 13C NMR (125.77 MHz, DMSO-d6, rotamer): δ 27.3-27.5(18C,tBu),46.7 / 46.7,60.6(2C),60.7(2C),69.6(2C),69.7,69.9,70.4 (3C),72.2,82.1,82.1,82.9,82.9,83.3,83.4,108.0,110.8,118.4,120.1(2C),12 3.1, 125.2 / 125.3, 127.0(4C), 127.6(4C), 140.7(2C), 143.8, 146.9, 149.5, 156.6, 157.1, 162.4 / 162.4. HRMS: m / z calculated for [C60H85N7O19+H]: 1208.5980, found: 1208.5959.

[0138] [ka]

[0139] (4-Chloro-pyridin-2-yl)-carbamic acid tert-butyl ester (5) To a stirred solution of 2-amino-4-chloropyridine (1) (50.00 g, 0.39 mol) in 556 mL of anhydrous THF in an ice bath, Et3N (81.37 mL, 0.58 mol) was added dropwise over 10 min in an inert atmosphere. After stirring for another 10 min at the same temperature, Boc2O (84.88 g, 0.39 mol) in THF (100 mL) was added dropwise over 30 min, followed by the addition of a catalytic amount of DMAP (4.75 g, 0.04 mol). After stirring overnight at room temperature, the reaction mixture was diluted with ethyl acetate (200 mL). The combined organic layers were filtered through a sintered funnel and the filtrate was washed with a saturated solution of NaHCO3 and dried over Na2SO4. The solvent was removed on a rotary evaporator to give the pure product. Yield: 67.59 g, 76%. 1 H NMR (300.13 MHz, CDCl3): δ 1.54(s,9H),6.95(dd,J=5.5,1.8 Hz,1H),8.12(d,J=1.9 Hz,1H),8.24(d,J=5.5 Hz,1H),9.96(s,1H), 13C NMR(125.77 MHz,CDCl3):δ 28.5(3C),81.5,112.9,118.7,146.2,148.3,152.6,153.8,ESI-MS:[C 10 H 13 Calculated m / z for ClN2O2+H]: 229.1, found: 229.2.

[0140] [ka]

[0141] Ethyl 2-((tert-butoxycarbonyl)amino)-4-chloronicotinate (6) To a stirred solution of (4-chloro-pyridin-2-yl)carbamic acid tert-butyl ester (30.50 g, 0.13 mol) in 534 mL of anhydrous THF in a dry ice-acetone bath (-78 °C) was added n-BuLi (24.86 mL, 0.27 mol, 11 M) dropwise over 1 h under inert atmosphere. After stirring for another 30 min at -78 °C, ClCO2Et (13.93 mL, 0.15 mol) was added dropwise over 10 min. The reaction progress was checked by TLC and after complete consumption of the starting material, the reaction mixture was quenched slowly with 1% HCl (200 mL). The resulting reaction mixture was transferred to a separatory funnel containing 10% HCl (50 mL) and EA (200 mL). The crude product was extracted from the aqueous layer with EA and the combined organic layers were dried over Na2SO4. The resulting solvent was removed on a rotary evaporator and the resulting crude material was purified by column chromatography to give ethyl 2-((tert-butoxycarbonyl)amino)-4-chloronicotinate as a pale yellow solid. Yield: 29.68 g, 74%. 1 H NMR(500.13 MHz,CDCl3):δ 1.40(t,J=7.2 Hz,3H),1.50(s,9H),4.41(q,J7.2 Hz,2H),7.08(d,J=5.2 Hz,1H),8.31(d,J=5.2 Hz,1H),8.62(s,1H), 13C NMR(125.77 MHz,CDCl3):δ 14.1,28.3(3C),62.3,81.8,120.8,144.7,149.9,150.0,151.3,151.8,164.9,HRMS:[C 13 H 17 Calculated m / z for ClN2O4+Na: 323.0774, found: 323.0777.

[0142] [ka]

[0143] Ethyl 2-amino-4-chloronicotinate (7) Ethyl 2-((tert-butoxycarbonyl)amino)-4-chloronicotinate (29.00 g, 0.10 mol) was added (slow addition) to a mixture of concentrated HCl (52.60 mL, 0.58 mol) and dichloromethane (64 mL) at room temperature. After 2 h at room temperature, completion of starting material was monitored by TLC, then the reaction mixture was cooled to 0° C. and neutralized with 2N NaOH solution. The reaction mixture was transferred to a separatory funnel containing 100 mL of dichloromethane and the compound was extracted from the aqueous layer into the organic layer. The combined dichloromethane layers were dried over anhydrous Na2SO4 and concentrated. The crude material was purified by silica gel column chromatography to give pure ethyl 2-amino-4-chloronicotinate as a white solid. Yield: 18.38 g, 95%. 1 H NMR (500.13 MHz, CDCl3): δ 1.41(t,J=7.1Hz,3H),4.42(q,J=7.1 Hz,2H),6.13(bs,2H),6.68(d,J=5.3 Hz,1H),7.97(d,J=5.4 Hz,1H), 13 C NMR (125.77 MHz, CDCCl3): δ 14.2, 61.8, 108.3, 115.9, 145.6, 151.2, 159.9, 166.4; HRMS: m / z calculated for [C8H9ClN2O2+H]: 201.0431; found: 201.0422.

[0144] [ka]

[0145] Ethyl 2-amino-4-chloro-5-bromonicotinate (8) To a solution of 7 (18.00 g, 0.09 mol) in anhydrous DMF was added NBS (18.36 g, 0.10 mol) in several portions at room temperature. Analysis of the resulting solution by TLC showed that 8 was completely consumed after 4 h. The resulting mixture was quenched with water (100 mL) and extracted with ethyl acetate (EA, 2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate (Na2SO4), filtered and concentrated. The resulting residue was purified by column chromatography on silica gel (100-200 mesh) to give exclusively ethyl 2-amino-4-chloro-5-bromonicotinate (8) as a pale yellow solid. Yield: 22.07 g, 88%. 1 H NMR (500.13 MHz, CDCl3): δ 1.41 (t, J = 7.1 Hz, 3H), 4.43 (q, J = 7.1 Hz, 2H), 5.86 (s, 2H), 8.24 (s, 1H), 13 C NMR (125.77 MHz, CDCl3): δ 14.2, 62.3, 109.7, 110.4, 144.4, 152.8, 158.0, 165.9. HRMS: m / z calculated for [C8H8BrClN2O2+H]: 278.9536, found: 278.9541.

[0146] [ka]

[0147] Ethyl 2-((tert-butoxycarbonyl)amino)-4-chloro-5-bromonicotinate (9) To an ice-cold solution of 8 (20.00 g, 71.55 mmol) in anhydrous dichloromethane (CH2Cl2), diisopropylethylamine (DIEA, 27.42 mL, 157.41 mmol) was added followed by triphosgene (7.64 g, 25.76 mmol). After 1 h at 0° C., tert-butanol (33.96 mL, 357.76 mmol) was added over 5 min and the ice bath was removed. The reaction progress was monitored by TLC and after 24 h at room temperature, the starting material was completely consumed. The resulting mixture was quenched with water and extracted with dichloromethane (CH2Cl2, 2×100 mL). The combined organic layers were washed with brine, saturated sodium bicarbonate (NaHCO3) solution, dried over anhydrous sodium sulfate, filtered and concentrated. The crude material obtained was purified by silica gel column chromatography (100-200 mesh) to give ethyl 2-((tert-butoxycarbonyl)amino)-4-chloro-5-bromonicotinate (5) as a white solid. Yield: 13.58g, 50%. 1 H NMR (500.13 MHz, CDCl3): δ 1.41 (t, J=7.2 Hz, 3H), 1.50 (s, 9H), 4.42 (q, J7.2 Hz, 2H), 8.37 (s, 1H), 8.57 (s, 1H), 13 C NMR(125.77 MHz,CDCl3):δ 14.1,28.3(3C),62.6,82.2,113.9,116.3,119.9,144.0,149.5,151.7,164.2, HRMS:[C 13 H 16 Calculated m / z for [BrClN2O4+H]: 379.0060, found: 379.0063.

[0148] [ka]

[0149] 5-Bromo-2-((tert-butoxycarbonyl)amino)-4-chloronicotinic acid (10) 41.41 mL of 1 M sodium hydroxide (118.53 mmol) was added to a mixture of 9 (10.00 g, 26.34 mmol) in ethanol:THF (3:1, 76 mL) at 0 °C over 15 min. After complete consumption of starting material as monitored by TLC, the reaction mixture was concentrated. The resulting crude material was transferred to a separatory funnel containing water (200 mL), extracted with EA (1 x 100 mL) and the organic layer was discarded. To the aqueous layer, 10% HCl (200 mL) and EA (100 mL) were carefully added (PH approx. 3-5). The compound was extracted into the EA layer, dried over anhydrous sodium sulfate and concentrated to give pure 5-bromo-2-((tert-butoxycarbonyl)amino)-4-chloronicotinic acid (10) as a pale yellow solid. Yield: 6.02 g, 65%. 1 H NMR (500.13 MHz, DMSO-d6): δ 1.43 (s, 9H), 8.69 (s, 1H), 9.88 (s, 1H), 13 C NMR(125.77 MHz,DMSO-d6):δ 27.9(3C),80.1,116.3,124.5,141.2,148.8,150.8,152.6,164.1,HRMS:[C 11 H 12 Calculated m / z for [BrClN2O4+H]: 350.9747, found: 350.9712.

[0150] [ka]

[0151] (11) It was difficult to purify this compound by column chromatography. Therefore, we proceeded to the next step without purification or analysis. HRMS: m / z [C 17 H 23 Calculated for [BrClN5O5+H]: 492.0649, found: 492.0655.

[0152] [ka]

[0153] Di-tert-butyl (8-bromo-4-oxo-3,4-dihydropyrido[4,3-d]pyrimidine-2,5-diyl) dicarbamate (12) To an ice-cold solution of 10 (5.00 g, 11.07 mmol) in anhydrous dimethylformamide (DMF, 28 mL) was added N-methylmorpholine (NMM, 1.64 mL, 14.94 mmol), followed by chloroethylformate (1.63 mL, 13.84 mmol). After 1 h at 0 °C, Boc-guanidine (2.38 g, 14.94 mmol) was added in one portion and the ice bath was removed. The progress of the reaction was monitored by TLC and after 24 h at room temperature, the starting material was completely consumed. The resulting mixture was concentrated to dryness to give the Boc-guanidine adduct as a crude mixture to which water was added and stirred at room temperature for 10 min. The resulting solid was filtered through filter paper and dried under vacuum overnight. To the ice-cold solution of the resulting solid in anhydrous DMF, NaH (60%, 1.77 g, 44.28 mmol) was carefully added. After 24 h, DMF was removed under vacuum and water was carefully added. The resulting solid was collected by filtration and dried in vacuum. The crude material was purified by silica gel column chromatography (100-200 mesh) to give 12 as a yellow solid. Yield: 3.64 g, 72% (over two steps). 1 H NMR (500.13 MHz, DMSO-d6): δ 1.48 (s, 9H), 1.50 (s, 9H), 8.54 (s, 1H), 10.85 (s, 1H), 11.58 (s, 1H), 11.78 (s, 1H), 13 C NMR(125.77 MHz,DMSO-d6):δ 27.7(3C),27.8(3C),80.3,83.2,103.2,109.2,149.0,150.4,152.0,152.6,153.7,154.2,161.7,HRMS:[C 17 H 22 Calculated m / z for [BrN5O5+H]: 456.0883, found: 456.0890.

[0154] [ka]

[0155] (8-bromo-4-(tert-butoxy)pyrido[4,3-d]pyrimidine-2,5-diyl)bis((tert-butoxycarbonyl)-carbamate)di-tert-butyl (13) To a solution of 12 (3.10 g, 6.79 mmol) in anhydrous THF was added DIEA (3.50 mL, 20.38 mmol) and DMAP (0.17 g, 1.36 mmol), followed by Boc2O (5.93 g, 27.18 mmol) at room temperature. After 4 h at room temperature, Boc2O (2.97 g, 13.59 mmol) was added and the reaction mixture was warmed to 50 °C. The consumption of starting material was monitored by TLC and after 24 h, the reaction mixture was then diluted with a saturated solution of NaHCO3 and EA. The organic layer was separated from the aqueous layer and dried over sodium sulfate. The solvent was removed under vacuum and the resulting crude material was purified by silica gel column chromatography to give pure 13 as a white solid. Yield: 3.15 g, 65%. 1 H NMR (500.13 MHz, DMSO-d6): δ 1.27 (s, 18H), 1.45 (s, 18H), 1.65 (s, 9H), 9.06 (s, 1H), 13 C NMR(125.77 MHz,DMSO-d6):δ 27.2(6C),27.4(6C),27.5(3C),82.7(2C),83.8(2C),87.6,109.7,118.2,148.7,148.8(2C),149.6(2C),150.8,155.0,156.4,166.5, HRMS:[C 31 H 46 Calculated m / z for [BrN5O9+H]: 712.2557, found: 712.2540.

[0156] [ka]

[0157] (8-allyl-4-(tert-butoxy)pyridol-4,3-dipyrimidine-2,5-diyl)bis((tert-butoxycarbonyl)carbamate)di-tert-butyl (14) To a stirred and degassed solution of 13 (3.00 g, 4.21 mmol) in anhydrous toluene (21 mL) was added allyltributyltin (2.79 g, 8.42 mmol) followed by tetrakistriphenylphosphinepalladium(0) (0.49 g, 0.42 mmol) at room temperature. The resulting solution was flushed with argon to create an inert atmosphere and the solution was refluxed at 125 °C for 15 h. The resulting mixture was cooled to room temperature, silica gel was added, the solvent was removed under vacuum, and the slurry was loaded onto a silica gel column chromatography to give 14 as a pale yellow solid. Yield: 1.70 g, 60%. 1 H NMR(500.13 MHz,CDCl3):δ 1.32(s,18H),1.47(s,18H),1.71(s,9H),3.78(dq,J=6.6,1.3 Hz,2H),4.94-5.15(m,2H),6.09(ddt,J=16.7,10.1,6.4 Hz,1H),8.49(s,1H), 13 C NMR(125.77 MHz, CDCl3):δ 27.8(6C),27.9(6C),28.2(3C),32.4,82.4(2C),83.3(2C),86.3,108.8,116.5, 131.4,136.0,148.1(2C),149.8(2C),150.3(2C),155.6,156.8,167.1,HRMS:[C 34 H 51 Calculated m / z for N5O9+H]: 674.3765, found: 674.3746.

[0158] [ka]

[0159] 2-(2,5-bis(bis(tert-butoxycarbonyl)amino)-4-(tert-butoxy)pyrido[4,3-d]pyrimidin-8-yl)acetic acid (15,E) To an ice-cold stirred solution of 14 (1.00 g, 1.48 mmol) in CH3CN:CCl4:H2O (23:23:34 mL) was added NaI04 (2.54 g, 11.87 mmol) followed by ruthenium(III) chloride hydrate (0.07 g, 0.30 mmol). After 2 h at 0 °C, the reaction mixture was filtered through a bed of Celite and concentrated to 3 / 4 volume under vacuum at 35 °C. To this mixture was added water (20 mL) and EA (20 mL) at 25 °C. The organic layer was separated from the aqueous layer and dried over sodium sulfate. The resulting solvent was removed under vacuum and the crude material was purified by silica gel column chromatography to give 15(E) as a light brown solid. Yield: 0.51 g 50%. 1 H NMR (300.13 MHz, CDCl3): δ 1.34 (s, 18H), 1.56 (s, 18H), 1.71 (s, 9H), 4.03 (s, 2H), 8.62 (s, 1H), 13 C NMR(125.77 MHz, CDCl3):δ 28.0(6C),28.1(6C),28.3(3C),37.1,83.2(2C),85.1(2C),87.7,109.0,124 .5,149.6,149.9(2C),150.1,155.9(2C),156.5(2C),167.4,170.4,HRMS:[C 33 H 49 N5O 11 Calculated m / z for [+H]: 692.3507, found: 692.3491.

[0160] [ka]

[0161] 4-Amino-2-(methylthio)pyrimidine-5-carbonitrile (17) A mixture of 2-(ethoxymethylene)malononitrile (100.00 g, 0.82 mol), S-methylisothiourea hemisulfate (73.81 g, 0.82 mol), triethylamine (370.92 mL, 2.66 mol) in absolute ethanol (819 mL) was stirred at room temperature. After two days, the solvent was removed under vacuum and the resulting residue was washed with water to give the desired compound as a white solid. Yield: 122.48 g, 90%. 1 H NMR (500.13 MHz, DMSO-d6): δ 2.45 (s, 3H), 7.87 (s, 2H), 8.43 (s, 1H), 13 C NMR (125.77 MHz, DMSO-d6): δ 13.4, 85.3, 115.6, 160.5, 161.4, 174.6; ESI-MS: m / z calculated for [C6H6N4S+H]: 167.0; found: 167.1.

[0162] [ka]

[0163] 4-Amino-N'-hydroxy-2-(methylthio)pyrimidine-5-carboximidamide (18) A mixture of 17 (50.00 g, 0.30 mol), hydroxylamine hydrochloride (24.04 g, 0.35 mol), and triethylamine (83.92 mL, 0.60 mol) in methanol (602 mL) was refluxed at 75° C. After two days, the reaction mixture was cooled to room temperature and the precipitated solid was collected by filtration and washed with methanol and hexane to give 18 as a pale yellow solid. Yield: 46.15 g, 77%. 1 H NMR (500.13 MHz, DMSO-d6): δ 2.43 (s, 3H), 5.96 (s, 2H), 7.59 (s, 1H), 8.10 (s, 1H), 8.35 (s, 1H), 9.87 (s, 1H), 13 C NMR (125.77 MHz, DMSO-d6): δ 13.2, 103.6, 149.9, 152.8, 159.6, 169.3; ESI-MS: m / z calculated for [C6H9N5OS+H] 200.1; found: 200.0.

[0164] [ka]

[0165] (E)-N'-Acetoxy-4-amino-2-(methylthio)pyrimidine-5-carboximidamide (19) To a solution of 18 (31.00 g, 0.16 mol) in glacial acetic acid was added acetic anhydride (51.48 mL, 0.55 mol) at room temperature. Analysis of the resulting solution by TLC showed that 18 was completely consumed after 15 h. The acetic acid was removed under vacuum and to the crude material was added saturated sodium bicarbonate solution and EA (200 mL each) (pH-8~9). The aqueous layer was extracted twice with EA and the organic layer was dried over sodium sulfate. EA was removed under vacuum to give pure 19 as a white solid. Yield: 28.02 g, 90%. 1 H NMR (500.13 MHz, DMSO-d6): δ 2.15 (s, 3H), 2.45 (s, 3H), 6.89 (s, 2H), 7.78 (s, 1H), 7.96 (s, 1H), 8.40 (s, 1H), 13 C NMR(125.77 MHz,DMSO-d6):δ 13.3,19.5,102.4,154.5,154.6,159.8,167.9,171.3, HRMS:[C8H 11 Calculated m / z for N5O2S+H] 242.0712, measured: 242.0718.

[0166] [ka]

[0167] 4-Amino-2-(methylthio)pyrimidine-5-carboximidamide (20) A mixture of 19 (25.00 g, 0.10 mol), formic acid (97.73 mL, 2.59 mol), and palladium on charcoal (10%, 5.51 g, 5.18 mmol) in methanol (130 mL) was refluxed at 80 °C. After 15 h, the reaction mixture was cooled to room temperature and the solvent was removed under vacuum to give the desired product as the formate salt. Yield of product as the formate salt: 29.96 g, 80%. (For NMR analysis: To the resulting crude material (1 g), methanol (10 mL) and TEA (5 mL, pH-9 to 10) were added and stirred for 15 min. The resulting solid was collected by filtration and washed with hexane. 1 H NMR (500.13 MHz, DMSO-d6): δ 2.43 (s, 3H), 5.96 (s, 2H), 7.59 (s, 1H), 8.11 (s, 1H), 8.36 (s, 1H), 9.87 (s, 1H), 13 C NMR (125.77 MHz, DMSO-d6): δ 13.3, 103.6, 149.9, 152.9, 159.6, 169.4; HRMS: m / z calculated for [C6H9N5S+H] 184.0657; found: 184.0664.

[0168] [ka]

[0169] tert-Butyl ((4-amino-2-(methylthio)pyrimidin-5-yl)(imino)methyl)carbamate (21) To an ice-cold stirred solution of 20 (22.00 g, 68.47 mmol) as the formate salt in THF:water (100:125 mL) was added sodium bicarbonate in portions (34.51 mL, 0.41 mol). When the pH of the resulting solution reached 8-9, Boc-anhydride (17.19 g, 78.74 mmol) in 25 mL of THF was added slowly. Analysis of the resulting solution by TLC showed that 20 was completely consumed after 24 h. The reaction mixture was transferred to a separatory funnel containing 100 mL of water and 200 mL of EA. The aqueous layer was extracted using EA (2×) and the combined EA layers were dried over sodium sulfate. EA was removed under vacuum and the mixture was purified by silica gel column chromatography to give pure 21 as a white solid. Yield: 15.71 g, 81%. 1 H NMR (300.13 MHz, CDCl3): δ 1.51 (s, 9H), 2.50 (s, 3H), 7.61 (s, 2H), 8.42 (s, 1H), 13 C NMR(125.77 MHz,CDCl3):δ 13.9,28.1(3C),79.6,104.6,155.2(2C),161.1(2C),173.9,HRMS:[C 11 H 17 Calculated m / z for N5O2S+H: 284.1181, measured: 284.1189.

[0170] [ka]

[0171] (Z)-((4-(bis(tert-butoxycarbonyl)amino)-2-(methylthio)pyrimidin-5-yl)((tert-butoxycarbonyl)imino)methyl)(tert-butoxycarbonyl)carbamate tert-Butyl (22) To an ice-cold stirred solution of 21 (15.00 g, 52.94 mmol) in THF (106 mL) was added DIPEA in one portion (46.11 mL, 264.69 mmol), DMAP (1.29 g, 10.59 mmol), followed by Boc-anhydride (57.77 g, 264.69 mmol) in 25 ml of THF (slow addition). The progress of the reaction was monitored by TLC and 21 was found to be completely consumed after 24 h. The reaction mixture was transferred to a separatory funnel containing 200 mL of water and 100 mL of EA. The mixture was extracted with EA (2×) and the combined EA layers were dried over sodium sulfate. EA was removed under vacuum and the crude mixture was purified by silica gel column chromatography to give pure 22 as a white solid. Yield: 28.96 g, 80%. 1 H NMR (500.13 MHz, CDCl3): δ 1.44(s,l8H),1.45(s,18H),1.51(s,9H),2.61(s,3H),8.69(s,1H), 13 C NMR(125.77 MHz, CDCl3):δ 14.6,28.0(6C),28.1(6C),28.1(3C),83.2,83.7(2C),84.9(2C),119.2,148.3,150.1,157.3(2C),158.8,159.5(2C),160.4,176.1,HRMS:[C 31 H50N5O 10 S+H] m / z calculated: 684.3278, found: 684.3275.

[0172] [ka]

[0173] Compound (23) To an ice-cold stirred solution of 22 (15.00 g, 21.94 mmol) in DCM (55 mL) was added mCPBA in portions (10.60 g, 61.42 mmol). The progress of the reaction was analyzed by TLC, which showed that 22 was completely consumed after 3 h. The reaction mixture was transferred to a separatory funnel containing 200 mL of a saturated solution of sodium bicarbonate and 100 mL of DCM. The mixture was extracted with DCM (2×) and the combined DCM layers were dried over sodium sulfate. The DCM was removed under vacuum and the crude mixture was used in the next step without further purification.

[0174] [ka]

[0175] (Z)-((4-(bis(tert-butoxycarbonyl)amino)-2-oxo-1,2-dihydro-pyrimidin-5-yl)((tert-butoxycarbonyl)imino)methyl)(tert-butoxycarbonyl)carbamate tert-butyl (24) To an ice-cold stirred solution of crude 23 (15.00 g) in THF (55 mL) was added 2N NaOH (54.84 mL, 109.68 mmol) slowly. Consumption of starting material was monitored by TLC. After 30 min, the reaction mixture was transferred to a separatory funnel containing 200 mL of 1% HCl and 100 mL of EA. The aqueous layer was extracted with EA (2×) and the combined EA layers were dried over sodium sulfate. EA was removed under vacuum and the crude material was purified by silica gel column chromatography. Yield: 10.75 g, 75% over two steps. 1 H NMR (300.13 MHz, DMSO-d6): δ 1.37 (s, 18H), 1.39 (s, 18H), 1.41 (s, 9H), 8.65 (s, 1H), 12.80 (s, 1H), 13 C NMR(125.77 MHz,DMSO-d6):δ 27.4(15C),82.0,82.9(2C),83.5(2C),108.0,145.2,147.5(2C),149.1(2C),152.8,155.0,157.0,162.9,HRMS:[C 30 H47 N5O 11 Calculated m / z for [+H] 654.3350, found: 654.3359.

[0176] [ka]

[0177] (Z)-2-(4-(bis(tert-butoxycarbonyl)amino)-2-oxo-5-(N,N,N´-tris(tert-butoxycarbonyl)carbamimidoyl)pyrimidin-1(2H)-yl)benzyl acetate (25) To a mixture of compound 24 (10.00 g, 15.30 mmol) and K2CO3 (4.23 g, 30.59 mmol) in anhydrous DMF (75 mL) was added 2-bromobenzyl acetate (2.42 mL, 15.30 mmol) dropwise over 10 min. The progress of the reaction was monitored by TLC and the reaction was found to be complete after 4 h. The reaction mixture was filtered through a sintered funnel and DMF was evaporated under vacuum. To the resulting crude material, water was added and stirred for 5 min. The resulting precipitate was collected by filtration and washed with water and hexane to obtain pure compound 25 as a white solid. (Note: if the compound does not precipitate sufficiently, extraction is an alternative method to obtain the compound, and if necessary, a short bed column is performed to obtain the pure compound). Yield: 10.92 g, 89%. 1 H NMR (500.13 MHz, CDCl3): δ 1.46(s,18H),1.48(s,18H),1.50(s,9H),4.75(s,2H),5.22(s,2H),7.27-7.47(m,5H),7.95(s,1H), 13 C NMR(125.77 MHz, CDCl3):δ 27.8(6C),27.9(6C),28.0(3C),51.0,68.2,83.0,83.7(2C),85.2(2C),110.6,128.6(3C),1 28.7(2C),128.8,134.5,148.2,149.5(2C),152.0(2C),154.4,157.1,163.9,166.1,HRMS:[C39 H 55 N5O 13 +H] calculated m / z 802.3875, found: 802.3882.

[0178] [ka]

[0179] (Z)-2-(4-(bis(tert-butoxycarbonyl)amino)-2-oxo-5-(N,N,N´-tris(tert-butoxycarbonyl)carbamimidoyl)pyrimid-1(2H)-yl)acetic acid (26, F) Palladium on charcoal (10% loading, 0.66 g, 0.62 mmol) was carefully added to a solution of 25 (5.00 g, 6.24 mmol) in EA (50 mL) under an argon balloon. After 5 min, the argon balloon was replaced with a hydrogen balloon and the reaction mixture was stirred for an additional 1 h under the same atmosphere. Complete consumption of starting material was judged by TLC. The resulting reaction mixture was carefully filtered through a bed of celite and the filtrate was rotary evaporated to give pure compound 26 as a white solid. Yield: 3.99 g, 90%. 1 H NMR (500.13MHz, DMSO-d6): δ1.36(s,18H), 1.41(s,18H), 1.42(s,9H), 4.85(s,2H), 9.10(s,1H), 13.45(s,1H), 13 C NMR(125.77MHz,DMSO-d6):0 27.4(6C), 27.4(6C), 27.5(3C), 50.9, 82.2, 83.0(2C), 83.3(2C), 108.3, 1 45.1, 146.9(2C), 149.4(2C), 154.1, 156.1, 157.0, 162.5, 168.4, HRMS:[C 32 H 49 N5O 13 +H] calculated m / z: 712.3405, found: 712.3386.

[0180] [ka]

[0181] 2-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acetic acid (27) This compound was purchased from a commercially available source.

[0182] [ka]

[0183] (R)-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-(2-(tert-butoxy)ethoxy)ethoxy)propyl)allyl glycinate (28) To a cooled solution of N-Fmoc(O-MP(tButyl)-L-serinol (5.00 g, 10.93 mmol) in saturated DCM:water (28 mL) was added Dess-Martin periodinane (9.96 g, 23.49 mmol) in several portions. The reaction mixture was stirred at the same temperature for another 30 min and at room temperature for 1 h to allow complete conversion of the alcohol to the aldehyde. The reaction mixture was diluted with ether, a saturated solution of sodium bicarbonate, 10% sodium thiosulfate, and stirred for 5 min. The entire reaction mixture was transferred to a separatory funnel and the organic compounds were extracted into ether (2x). The ether layer was dried over sodium sulfate and removed on a rotary evaporator to give the crude aldehyde. The aldehyde could be further purified. The aldehyde was used in the next step without any distillation. To the aldehyde in anhydrous DCM (44 mL) was added glycinate allyl PTSA salt (6.28 g, 21.86 mmol) and DIEA (5.90 mL, 33.89 mmol) and allowed to react for 1 h. NaB(OAc)3H (5.79 g, 27.33 mmol) was added in one portion to the reaction mixture. After stirring overnight at room temperature, the reaction mixture was diluted with DCM (100 mL) and a saturated solution of sodium bicarbonate. The reaction mixture was transferred to a separatory funnel and the layers were separated from the aqueous layer. The combined organic layers were dried over sodium sulfate, removed on a rotary evaporator, and the crude mixture was purified by flash silica gel column chromatography. Yield: 4.85 g, 85%. 1H NMR (500.13 MHz, CDCl3): δ 1.19(s,9H),2.77-2.92(m,2H),3.49-3.69(m,13H),3.88(bs,1H),4.23(t,J=6.9 Hz,1H),4.39(d,J=7.5 Hz,2H),4.64(dt,J=5.9,1.4 Hz,2H),5.23-5.36(m,2H),5.73(d,J=8.4 Hz,1H),5.92(ddt,J=17.3,10.4,5.8 Hz,1H),7.32(td,J=7.5,1.2 Hz,2H),7.36-7.43(m,2H),7.60-7.68(m,2H),7.74-7.79(m,2H), 13 C NMR (125.77 MHz, CDCl3): δ 27.5(3C),47.3,50.3,50.5,50.6,50.7,61.2,65.5,66.7,70.5,70.8,71.2,71.4,73.1,118.7,119.9, 120.0,120.0,125.2,127.0,127.6,127.7,131.8,141.3,144.0,144.0,156.4,171.8,174.3, ESI-MS:[C 31 H 42 N2O 71 +H]のm / zのcalculated value: 555.3, measured value: 555.3.

[0184]

change

[0185] アリルモノマー(29a) To a mixture of 15(E) (0.50 g, 0.72 mmol) and DIEA (163.67 μL, 0.94 mmol) in anhydrous DMF (6 mL) was added HBTU (0.32 g, 0.83 mmol) in one portion at room temperature. After 10 min at room temperature, scaffold 28 (0.60 g, 1.08 mmol) in DMF (4 mL) was added to the above reaction mixture. The progress of the reaction was monitored by TLC (eluent: EA:Hex (50:50), scaffold Rf = 0.2, product Rf = 0.6, E Rf = 0.1). After complete consumption of starting material, DMF was removed under vacuum at 45 °C. To the resulting crude material, 1% HCl (20 mL) and EA (20 mL) were added and the organic layer (2x) was separated from the aqueous layer using a separatory funnel. The combined organic layers were dried and removed and the crude material obtained was purified by flash silica gel column chromatography. Yield: 0.62 g, 70%. 1 H NMR (500.13 MHz, DMSO-d6, rotamer): δ 1.08 / 1.09(s,9H),1.211.33(m,18H),1.36 / 1.38(s,18H),1.41 / 1.65(s,9H),3.36-3.70(m,10H),3.82-4.27(m,8 H),4.32(bs,2H),4.41-4.71(m,2H),5.13-5.41(m,2H),5.81-6.01(m,1H),7.30-7.57(m,5H),7.71 / 7.73(d,J=9.7 Hz,2H),7.89 / 7.99(d,J=7.5 Hz,2H),8.56 / 8.60(s,1H), 13 C NMR (125.77 MHz, DMSO-d6, rotamer): δ 27.2-27.6(18C),46.7,59.7,60.6 / 60.6,64.7,65.3,65.5,69.6,69.6,69.8,70. 0,70.4,70.4,72.2,81.8-86.3(6C),108.1,117.7,118.2,120.l(2C),125.1,127. 0(2C),127.3,127.6(2C),127.8 / 127.9,132.1,132.3,140.7,143.8,147.9,149. 3,149.5,149.6,155.0 / 155.1,155.9,156.5,166.6,168.8,169.2,170.2,HRMS:[C64 H 89 N7O 17 Calculated m / z for [+H]: 1228.6393, found: 1228.6398.

[0186] [ka]

[0187] Allyl Monomer (29b) This compound was prepared using the procedure described above for compound 29a, starting with compound 27 (1.00 g, 5.88 mmol) and scaffold 28 (4.08 g, 7.35 mmol). TLC (eluent: 5% MeOH:DCM (5:95), scaffold Rf = 0.6, product Rf = 0.2, 27 Rf = 0.0). Yield: 3.5 g, 84%. 1 H NMR (500.13 MHz, DMSO-d6, rotamer): δ 1.10 / 1.10(s,9H),3.30-3.59(m,14H),3.744.13(m,2H),4.174.42(m,4H),4.60(dd,J=33.4,4.8 Hz,2H),5.00-5.44(m,2H),5.82-6.01(m,1H),7.10-7.55(m,6H),7.69(d,J=7.4 Hz,2H),7.89(d,J=7.5 Hz,2H),10.75(bs,1H),11.08(s,1H), 13 C NMR (125.77 MHz, DMSO-d6, rotamer) δ 27.2(3C),46.7,60.6(2C),64.7,65.2,65.5,69.6,69.8,69.9,70.4(2C),72.2,107.2,117.7,118.1,120.1(2C),125.2,127.0(2C),1 27.3,127.6(2C),132.2 / 132.3,139.2,139.7,140.7,143.8 / 143.8,151.2 / 151.3,155.8,164.1 / 164.1,168.9,169.4,170.6,HRMS:[C 37 H 46 N4O 10 +H] calculated m / z: 707.3292, found: 707.3290.

[0188] [ka]

[0189] Allyl Monomer (29c) This compound was prepared using the procedure described above for compound 29a, starting with compound 26 (3.50 g, 4.92 mmol) and scaffold 28 (3.41 g, 6.15 mmol). TLC (eluent: EA:Hex (40:60), scaffold Rf=0.1, product Rf=0.7, 26 Rf=0.1). Yield: 4.80 g, 78%. 1 H NMR(300 MHz,DMSO-d6):δ 1.09(bs,9H),1.34 / 13.6(s,18H),1.41 / 1.42(s,27H),3.35-3.59(m,14H),4.07-4.49(m,4H),4.61(dd,J=37.6,5.4 Hz,3H),4.97-5.42(m,3H),5.77-6.04(m,1H),7.32(t,J=7.5 Hz,2H),7.50-7.57(m,3H),7.89(d,J=7.5 Hz,2H),7.99(d,J=8.4 Hz, 2H), 8.94 / 8.96(s, 1H), 13 C NMR (125.77 MHz, DMSO-d6, rotamer): δ 27.2-27.5(18C),46.7,60.2 / 60.7(2C),64.7,65.5,69.5,69.6,69.8,69. 9,70.4 / 70.4(2C),72.2,82.2-83.4(6C),108.1,117.7,120.1(2C),124.4, 125.1,127.0(2C),127.4,127.6(2C),127.8,132.2(2C),140.7(2C),143. 8(2C),145.1,146.9(2C),149.5(2C),157.0,162.5,166.5,168.4,HRMS:[C 63 H 89 N7O 19 +H] calculated dm / z 1248.6291, found 1248.6256.

[0190] Non-limiting aspects of the present invention are described in the following numbered clauses.

[0191] Clause 1: A genetic recognition reagent comprising a nucleic acid or nucleic acid analog backbone and comprising three or more ribose, deoxyribose, or nucleic acid analog backbone residues, a sequence of divalent nucleobases bound to the backbone residues, wherein the sequence of divalent nucleobases binds to a unit target sequence, or one or more sequential repeats of a unit target sequence, of an expanded repeat of a repeat expansion disease on two nucleic acid strands.

[0192] Clause 2: The genetic recognition reagent of clause 1, wherein the nucleic acid or nucleic acid analog backbone comprises a first end and a second end, and further comprises a first linking group attached to the first end of the backbone, and a second linking group attached to the second end which is non-covalently bound or self-ligated to the first linking group.

[0193] Clause 3: The genetic recognition reagent described in clause 1 or 2, wherein the sequence of the bivalent nucleic acid bases binds to a unit target sequence or two or more sequential repeats of the unit target sequence of an expanded repeat of a repeat expansion disease on each of the two strands when the two strands are aligned in an antiparallel orientation.

[0194] Clause 4: The target unit sequence is, on both of the two strands, (GAA) n , (CGG) n , (CCG) n , (CAG) n , (CTG) n , (CCTG) n , (ATTCT) n , or (GGGGCC) n 4. The gene recognition reagent according to any one of clauses 1 to 3, wherein the gene recognition reagent is formed by a sequence that is complementary to any of the above, or a sequence that is a sequential repeat of the above.

[0195] Clause 5: The gene recognition reagent according to any one of clauses 1 to 4, wherein the target unit sequence is C / GA / AG / C.

[0196] Clause 6: A gene recognition reagent described in any one of clauses 1 to 5, wherein the nucleic acid base sequence is in the order of JB3 nucleic acid base, JB6 nucleic acid base, and JB4 nucleic acid base, JB6 nucleic acid base, JB4 nucleic acid base, and JB3 nucleic acid base, or JB4 nucleic acid base, JB3 nucleic acid base, and JB6 nucleic acid base, or two or more consecutive repeats of the above.

[0197] Clause 7: The gene recognition reagent according to clause 6, having the nucleic acid base sequences in the following order: JB3 or JB3b; JB6 or JB6b; and JB4, JB4b, JB4c, JB4d, or JB4e; JB6 or JB6b; JB4, JB4b, JB4c, JB4d, or JB4e; and JB3 or JB3b; or JB4, JB4b, JB4c, JB4d, or JB4e; JB3 or JB3b; and JB6 or JB6b; or two or more consecutive repeats of the above.

[0198] Clause 8: The gene recognition reagent according to any one of clauses 1 to 5, having the nucleic acid base sequences in the order of JB3, JB6, and JB4, JB6, JB4, and JB3, or JB4, JB3, and JB6, or successive repeats of two or more of the above.

[0199] Clause 9: A gene recognition reagent according to any one of clauses 1 to 3, having a nucleic acid base sequence of a unit recognition reagent sequence listed in Table C.

[0200] Clause 10: The gene recognition reagent according to any one of clauses 1 to 9, wherein the two strands are both of the same nucleic acid molecule.

[0201] Clause 11: The gene recognition reagent according to any one of clauses 1 to 10, wherein the two strands are both RNA.

[0202] Clause 12: The gene recognition reagent according to any one of clauses 1 to 11, consisting of a sequence of 3 to 8 nucleobases, such as 3, 4, 5, 6, 7, or 8 nucleobases.

[0203] Clause 13: The gene recognition reagent according to any one of clauses 1 to 12, wherein the backbone residue is a nucleic acid analog backbone residue.

[0204] Clause 14: The gene recognition reagent according to clause 13, wherein the backbone residues are conformationally preorganized.

[0205] Clause 15: The gene recognition reagent according to clause 14, wherein the backbone residues are locked nucleic acid residues.

[0206] Clause 16: The gene recognition reagent according to clause 14, wherein the backbone residues are peptide nucleic acid (PNA) residues.

[0207] Clause 17: The gene recognition reagent of clause 14, wherein said framework residues are γPNA residues.

[0208] Article 18: Construction: [ka]

[0209] wherein X is S or O, n is an integer from 1 to 6, m is an integer from 0 to 4, and R1 and R2 are each independently H, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] Linear or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, (C3-C8) cycloalkyl (C1-C6) alkylene, optionally substituted with ethylene glycol units containing 1 to 50 ethylene glycol moieties, -CH2-(OCH2-CH2) qOP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R3 is H or a leaving group, for example, a straight or branched (C1-C8) alkyl, a substituted or unsubstituted (C3-C8) aryl, a (C3-C8) aryl (C1-C6) alkylene, a (C1-C8) carboxy, an amino acid side chain, or a guanidine-containing group, or [ka] where o is 1 to 20, each R6 is independently an amino acid side chain, and R7 is -OH or -NH2; R4 is (C1~C 10 ) divalent hydrocarbon or (C1-C2) substituted with one or more N or O moieties, such as -O-, -OH, -C(O)-, -NH-, -NH2, -C(O)NH- 10 ) a divalent hydrocarbon, R5 is -OH, -SH or a disulfide protecting group, and Each of R independently generates a sequence of nucleic acid bases complementary to a unit target sequence of nucleic acid bases in one or more target nucleic acids, and thus each of the multiple recognition modules is a nucleic acid base that binds to a target sequence of nucleic acid bases on the template nucleic acid and ligates to each other, or a pharma- ceutically acceptable salt thereof.

[0210] Clause 19: R1 or R2 is -(OCH2-CH2) q OP1, -(OCH2-CH2) q -NHP1, -(SCH2-CH2) q -SP1, -(OCH2-CH2) r -OH, -(OCH2-CH2) r -NH2, -(OCH2-CH2) r -NHC(NH)NH2, or -(OCH2-CH2) r -SS[CH2CH2] s 19. The gene recognition reagent according to clause 18, wherein P1 is H, (C1-C6)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer of 0 to 50, r is an integer of 1 to 50, and s is an integer of 1 to 50.

[0211] Clause 20: The gene recognition reagent according to clause 18, wherein R5 is -SH, OH, or SS-R8, where R8 is one or more of an amino acid residue, an amino acid side chain, a guanidine-containing group, an unsubstituted or substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl(C1-C6) alkylene, or (C3-C8) cycloalkyl(C1-C6) alkylene.

[0212] Clause 21: The gene recognition reagent according to clause 18, wherein R1 is H and R2 is not H, or R2 is H and R1 is not H.

[0213] Clause 22: The gene recognition reagent according to clause 18, wherein R1 is H and R2 comprises a polyoxyethylene moiety.

[0214] Clause 23: The gene recognition reagent according to clause 18, wherein R5 is -SH and X is S.

[0215] Clause 24: The genetic recognition reagent described in clause 18, wherein R5 comprises a lysine residue, an arginine residue, or a guanidine-containing group.

[0216] Clause 25: The genetic recognition reagent according to clause 18, wherein R4 is methylene, R5 is -SH, X is S, and R5 is a hydroxyl-substituted (C1-C8) alkyl, such as -CH2-CH2-OH.

[0217] Clause 26: A gene recognition reagent according to any one of clauses 2 to 14, wherein the first linking group and the second linking group are independently 2-5 ring fused polycyclic aromatic moieties that stack with aryl moieties of adjacent recognition reagents when the recognition reagent hybridizes to adjacent sequences of a target nucleic acid.

[0218] Clause 27: The gene recognition reagent according to Clause 26, wherein the 2-5 ring fused polycyclic aromatic moiety is unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B2), mangosteen, or mangiferin.

[0219] Clause 28: The gene recognition reagent according to clause 26 or 27, wherein the 2- to 5-ring fused polycyclic aromatic moieties are identical.

[0220] Clause 29. The recognition reagent has the structure: [ka] having wherein each R is independently a nucleobase and each R can be the same or a different nucleobase; n is an integer ranging from 1 to 6, for example, 1, 2, 3, 4, 5, or 6; R1 and R2 are each independently H, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] , unsubstituted or substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, or (C3-C8) cycloalkyl (C1-C6) alkylene, -CH2-(OCH2-CH2) q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(OCH2-CH2-O) q -SP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] sNHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R 10 or R 11 On the other hand, R 12 , R 13 , or R 14 one of the R3 is -L-R3, where each R3 is independently a 2-5 ring fused polycyclic aromatic moiety, e.g., unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B2), mangosteen, or mangiferin, each of which is capable of stacking with the R3 group of an adjacent recognition reagent when the recognition reagent hybridizes to an adjacent sequence of a target nucleic acid; L is a linker, and R 10 , R 11 , R 12 , R 13 , and R 14 the remainder are each independently H, one or more contiguous amino acid residues, e.g., one or more Arg residues, a guanidine-containing group, e.g., [ka] where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. [ka] , unsubstituted or substituted (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C1-C8) hydroxyalkyl, (C3-C8) aryl, (C3-C8) cycloalkyl, (C3-C8) aryl (C1-C6) alkylene, or (C3-C8) cycloalkyl (C1-C6) alkylene, -CH2-(OCH2-CH2) q OP1, -CH2-(OCH2-CH2) q -NHP1, -CH2-(OCH2-CH2-O) q -SP1, -CH2-(SCH2-CH2) q -SP1, -CH2-(OCH2-CH2) r -OH, -CH2-(OCH2-CH2) r -NH2, -CH2-(OCH2-CH2) r -NHC(NH)NH2, or -CH2-(OCH2-CH2) r -SS[CH2CH2] s NHC(NH)NH2, where P1 is H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50, or 3. The gene recognition reagent according to claim 2, which is a pharma- ceutically acceptable salt thereof;

[0221] R1, R2, R under Clause 30:1 and above 10 , R 11 , R 12 , R 13 , or R 14 But -(OCH2-CH2) q OP1, -(OCH2-CH2) q -NHP1, -(SCH2-CH2) q -SP1, -(OCH2-CH2) r -OH, -(OCH2-CH2) r -NH2, -(OCH2-CH2) r -NHC(NH)NH2, or -(OCH2-CH2)r -SS[CH2CH2] s 30. The gene recognition reagent according to clause 29, wherein P1 is H, (C1-C6)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)aryl, (C3-C8)cycloalkyl, (C3-C8)aryl(C1-C6)alkylene or (C3-C8)cycloalkyl(C1-C6)alkylene, q is an integer from 0 to 50, r is an integer from 1 to 50, and s is an integer from 1 to 50.

[0222] Clause 31: A gene recognition reagent according to clause 29, wherein R4 and R7 are -L-R3.

[0223] Clause 32: The genetic recognition reagent of clause 29, wherein the linker comprises about 5 to 25 atoms, such as 5 to 20, 5 to 10, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms, or a total of 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C and heteroatoms, such as O, P, N, or S atoms.

[0224] Clause 33: The gene recognition reagent according to Clause 29, wherein each instance of R3 contains the same 2- to 5-ring fused polycyclic aromatic moiety.

[0225] Article 34: Guanidine-containing groups, such as [ka] wherein n=1, 2, 3, 4, or 5.

[0226] Clause 35: A method for binding a nucleic acid containing an expanded repeat associated with a repeat expansion disease, comprising contacting the nucleic acid containing the expanded repeat with a gene recognition reagent described in any one of clauses 1 to 32.

[0227] Clause 36. The nucleic acid comprises (GAA) on both of said two strands. n , (CGG) n , (CCG) n , (CAG) n , (CTG) n , (CCTG) n , (ATTCT) n , or (GGGGCC) n 36. The method of claim 35, comprising a unit target sequence formed by sequential repeats of:

[0228] Clause 37. The nucleic acid comprises (CAG) on both of said two strands. n 36. The method of claim 35, comprising a unit target sequence formed by sequential repeats of, or a sequence complementary thereto.

[0229] Clause 38: The method of any one of clauses 35 to 37, wherein said nucleic acid is obtained from a patient having a repeat expansion disorder.

[0230] Clause 39: A method of identifying the presence of a nucleic acid comprising an expanded repeat associated with a repeat expansion disease in a sample obtained from a patient, comprising contacting a nucleic acid sample obtained from said patient with a genetic recognition reagent according to any one of clauses 2 to 34, determining whether binding and ligation of said genetic recognition reagent occurs as an indication that said sample comprises a nucleic acid comprising an expanded repeat associated with a repeat expansion disease, and optionally treating said patient for said repeat expansion disease.

[0231] Clause 40: A composition comprising the gene recognition reagent according to any one of clauses 1 to 34 and a pharma- ceutically acceptable carrier.

[0232] Clause 41: A method of knocking down expression of a gene containing an expanded repeat associated with a repeat expansion disease in a cell, the method comprising contacting a nucleic acid, such as an RNA, comprising said expanded repeat with a gene recognition reagent according to any one of clauses 1 to 34.

[0233] The present invention has been described with reference to certain exemplary embodiments, dispersible compositions and their uses. However, those skilled in the art will recognize that various substitutions, modifications or combinations of any of the exemplary embodiments can be made without departing from the spirit and scope of the invention. Therefore, the invention is not limited by the description of the exemplary embodiments, but by the appended claims as first submitted.

Claims

1. A gene recognition reagent comprising a nucleic acid or nucleic acid analog backbone, three or more ribose, deoxyribose, or nucleic acid analog backbone residues, and a sequence of divalent nucleobases bound to the backbone residues, wherein the sequence of divalent nucleobases binds to a unit target sequence of an expanded repeat of a repeat expansion disease on two nucleic acid strands, or one or more sequential repeats of a unit target sequence.

2. The gene recognition reagent of claim 1, wherein the nucleic acid or nucleic acid analog backbone comprises a first end and a second end, and further comprises a first linking group attached to the first end of the backbone, and a second linking group attached to the second end which is non-covalently bound or self-ligated to the first linking group.

3. The gene recognition reagent of claim 2, wherein the sequence of divalent nucleic acid bases binds to a unit target sequence or two or more sequential repeats of the unit target sequence of an expanded repeat of a repeat expansion disease on each of the two strands when the two strands are aligned in an antiparallel orientation.

4. The target unit sequence is, on both of the two strands, (GAA) n , (CGG) n , (CCG) n , (CAG) n , (CTG) n , (CCTG) n , (ATTCT) n , or (GGGGCC) n 4. The gene recognition reagent according to claim 3, which is formed by sequential repeats of:

5. 4. The gene recognition reagent according to claim 3, wherein the target unit sequence is C / G-A / A-G / C.

6. The nucleic acid base sequence, JB3 nucleobase, JB6 nucleobase, and JB4 nucleobase, JB6 nucleobase, JB4 nucleobase, and JB3 nucleobase, JB4 nucleobase, JB3 nucleobase, and JB6 nucleobase, JB3 or JB3b, JB6 or JB6b, and JB4, JB4b, JB4c, JB4d, or JB4e, JB6 or JB6b, JB4, JB4b, JB4c, JB4d, or JB4e, and JB3 or JB3b, JB4, JB4b, JB4c, JB4d, or JB4e, JB3 or JB3b, and JB6 or JB6b, JB3, JB6, and JB4, JB6, JB4, and JB3, or 6. The gene recognition reagent according to claim 5, comprising JB4, JB3, and JB6, or successive repeats of two or more of the above, in that order.

7. The gene recognition reagent of claim 1, having a nucleic acid base sequence of the unit recognition reagent sequence listed in Table C.

8. The gene recognition reagent according to claim 1 , wherein the two strands are of the same nucleic acid molecule.

9. The gene recognition reagent according to claim 1 , wherein both of said two strands are RNA.

10. The gene recognition reagent according to claim 1, which consists of a sequence of 3 to 8 nucleobases, such as 3, 4, 5, 6, 7, or 8 nucleobases.

11. The gene recognition reagent according to claim 1 , wherein the backbone residue is a nucleic acid analog backbone residue.

12. The gene recognition reagent according to claim 11, wherein the backbone residues are conformationally preorganized.

13. The gene recognition reagent according to claim 14 , wherein the backbone residue is a locked nucleic acid residue.

14. The gene recognition reagent according to claim 14, wherein the backbone residue is a peptide nucleic acid (PNA) residue.

15. The gene recognition reagent according to claim 14, wherein the backbone residue is a γPNA residue.

16. structure: 【Chemistry 1】 having where X is S or O, n is an integer from 1 to 6, m is an integer from 0 to 4, and R 1 and R 2 are each independently H, a guanidine-containing group, e.g., 【Chemistry 2】 where n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. 【Chemistry 3】 Linear or branched (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 1 ~C 8 ) hydroxyalkyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene, (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, optionally substituted with ethylene glycol units containing 1 to 50 ethylene glycol moieties; 2 - (OCH 2 -CH 2 ) q OP 1 , -CH 2 - (OCH 2 -CH 2 ) q -NHP 1 , -CH 2 - (SCH 2 -CH 2 ) q -SP 1 , -CH 2 - (OCH 2 -CH 2 ) r -OH, -CH 2 - (OCH 2 -CH 2 ) r -NH 2 , -CH 2 - (OCH 2 -CH 2 ) r -NHC(NH)NH 2 , or -CH 2 - (OCH 2 -CH 2 ) r -S-S[CH 2 CH 2 ] s NHC (NH) NH 2 where P 1 is H, (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R 3 is H or a leaving group, e.g., linear or branched (C 1 ~C 8 ) alkyl, substituted or unsubstituted (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene, (C 1 ~C 8 ) carboxy, optionally substituted with an amino acid side chain, or a guanidine-containing group, or 【Chemistry 4】 where o is 1 to 20, and R 6 are each independently an amino acid side chain; R 7 is -OH or -NH 2 and R 4 (C 1 ~C 10 ) a divalent hydrocarbon or one or more N or O moieties, such as -O-, -OH, -C(O)-, -NH-, -NH 2 , substituted with —C(O)NH— (C 1 ~C 10 ) a divalent hydrocarbon, R 5 is —OH, —SH or a disulfide protecting group, and Each of R independently generates a sequence of nucleobases complementary to a target sequence of nucleobase units in one or more target nucleic acids, such that each of the plurality of recognition modules is a nucleobase that binds to a target sequence of nucleobases on the template nucleic acid and ligates to one another; or The gene recognition reagent according to claim 1, which is a pharma- ceutically acceptable salt thereof.

17. The R 1 Or the above R 2 But -(OCH 2 -CH 2 ) q OP 1 , -(OCH 2 -CH 2 ) q -NHP 1 , -(SCH 2 -CH 2 ) q -SP 1 , -(OCH 2 -CH 2 ) r -OH, -(OCH 2 -CH 2 ) r -NH 2 , -(OCH 2 -CH 2 ) r -NHC(NH)NH 2 , or -(OCH 2 -CH 2 ) r -S-S[CH 2 CH 2 ] s NHC (NH) NH 2 (C 1 ~C 6 ) alkyl, where P 1 is H, (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, q is an integer of 0 to 50, r is an integer of 1 to 50, and s is an integer of 1 to 50. The gene recognition reagent according to claim 18 .

18. The R 5 is -SH, OH, or S-S-R 8 wherein R 8 is one or more amino acid residues, amino acid side chains, guanidine-containing groups, unsubstituted or substituted (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 1 ~C 8 ) hydroxyalkyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene, or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 20. The gene recognition reagent according to claim 18, wherein:

19. The R 1 is H, and said R 2 is not H, or 2 is H, and said R 1 The gene recognition reagent according to claim 18 , wherein

20. The R 1 is H, and said R 2 The gene recognition reagent according to claim 18 , wherein comprises a polyoxyethylene moiety.

21. The R 5 The gene recognition reagent according to claim 18, wherein said X is -SH and said X is S.

22. The R 5 The gene recognition reagent according to claim 18 , wherein comprises a lysine residue, an arginine residue, or a guanidine-containing group.

23. The R 4 is methylene, and the R 5 is -SH, said X is S, and said R 5 is hydroxyl substituted (C 1 ~C 8 ) alkyl, e.g., —CH 2 -CH 2 The gene recognition reagent according to claim 18, which is -OH.

24. The genetic recognition reagent of claim 2, wherein the first linking group and the second linking group are independently 2-5 ring fused polycyclic aromatic moieties that stack with aryl moieties of adjacent recognition reagents when the recognition reagents hybridize to adjacent sequences of the target nucleic acid.

25. The 2-5 ring fused polycyclic aromatic moiety is unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B 2 ), mangosteen, or mangiferin.

26. The gene recognition reagent according to claim 24, wherein the 2- to 5-ring fused polycyclic aromatic moieties are identical.

27. The recognition reagent has the structure: 【Chemistry 5】 having Where: each R is independently a nucleobase and each R can be the same or a different nucleobase; n is an integer ranging from 1 to 6, for example, 1, 2, 3, 4, 5, or 6; R 1 and R 2 are each independently H, a guanidine-containing group, e.g., 【Chemistry 6】 Where: n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. 【Chemistry 7】 Unsubstituted or substituted (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 1 ~C 8 ) hydroxyalkyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene, or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, -CH 2 - (OCH 2 -CH 2 ) q OP 1 , -CH 2 - (OCH 2 -CH 2 ) q -NHP 1 , -CH 2 - (OCH 2 -CH 2 -O) q -SP 1 , -CH 2 - (SCH 2 -CH 2 ) q -SP 1 , -CH 2 - (OCH 2 -CH 2 ) r -OH, -CH 2 - (OCH 2 -CH 2 ) r -NH 2 , -CH 2 - (OCH 2 -CH 2 ) r -NHC(NH)NH 2 , or -CH 2 - (OCH 2 -CH 2 ) r -S-S[CH 2 CH 2 ] s NHC (NH) NH 2 where P 1 is H, (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; R 10 Or R 11 One of the two, and R 12 , R 13 , or R 14 One of them is -L-R 3 where R 3 each independently is a 2-5 ring fused polycyclic aromatic moiety, e.g., unsubstituted or substituted pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, fluoranthene, acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene / tetracene, pleiadene, picene, or perylene, optionally substituted with one or more heteroatoms such as O, N, and / or S, e.g., xanthene, riboflavin (vitamin B 2 ), mangostin, or mangiferin, each of which is an R of an adjacent recognition reagent when the recognition reagent hybridizes to an adjacent sequence of a target nucleic acid. 3 It can be stacked with the group L is a linker, and R 10 , R 11 , R 12 , R 13 , and R 14 each of the remainders is independently H, one or more contiguous amino acid residues, e.g., one or more Arg residues, a guanidine-containing group, e.g., 【Chemistry 8】 Where: n=1, 2, 3, 4, or 5; Amino acid side chains, e.g. 【Chemistry 9】 Unsubstituted or substituted (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 1 ~C 8 ) hydroxyalkyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene, or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, -CH 2 - (OCH 2 -CH 2 ) q OP 1 , -CH 2 - (OCH 2 -CH 2 ) q -NHP 1 , -CH 2 - (OCH 2 -CH 2 -O) q -SP 1 , -CH 2 - (SCH 2 -CH 2 ) q -SP 1 , -CH 2 - (OCH 2 -CH 2 ) r -OH, -CH 2 - (OCH 2 -CH 2 ) r -NH 2 , -CH 2 - (OCH 2 -CH 2 ) r -NHC(NH)NH 2 , or -CH 2 - (OCH 2 -CH 2 ) r -S-S[CH 2 CH 2 ] s NHC (NH) NH 2 where P 1 is H, (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, q is an integer from 0 to 50, and r and s are each independently an integer from 1 to 50; or The gene recognition reagent according to claim 2, which is a pharma- ceutically acceptable salt thereof.

28. R equal to or greater than 1 1 , R 2 , R 10 , R 11 , R 12 , R 13 , or R 14 But -(OCH 2 -CH 2 ) q OP 1 , -(OCH 2 -CH 2 ) q -NHP 1 , -(SCH 2 -CH 2 ) q -SP 1 , -(OCH 2 -CH 2 ) r -OH, -(OCH 2 -CH 2 ) r -NH 2 , -(OCH 2 -CH 2 ) r -NHC(NH)NH 2 , or -(OCH 2 -CH 2 ) r -S-S[CH 2 CH 2 ] s NHC (NH) NH 2 (C 1 ~C 6 ) alkyl, where P 1 But, H, (C 1 ~C 8 ) alkyl, (C 2 ~C 8 ) alkenyl, (C 2 ~C 8 ) alkynyl, (C 3 ~C 8 ) aryl, (C 3 ~C 8 ) cycloalkyl, (C 3 ~C 8 ) Aryl (C 1 ~C 6 ) alkylene or (C 3 ~C 8 ) Cycloalkyl(C 1 ~C 6 ) alkylene, q is an integer of 0 to 50, r is an integer of 1 to 50, and s is an integer of 1 to 50. The gene recognition reagent according to claim 27,

29. The R 4 and the R 7 Ga-L-R 3 The gene recognition reagent according to claim 27 ,

30. The gene recognition reagent according to claim 27, wherein the linker comprises about 5 to 25 atoms, e.g., 5 to 20, 5 to 10, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms, or a total of 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C and heteroatoms, e.g., O, P, N, or S atoms.

31. The R 3 The gene recognition reagent according to claim 27, wherein each of the above formulas contains the same 2- to 5-ring fused polycyclic aromatic moiety.

32. Guanidine-containing groups, such as 【Chemistry 10】 wherein n=1, 2, 3, 4, or 5.

33. A method for binding a nucleic acid containing an expanded repeat associated with a repeat expansion disease, comprising contacting the nucleic acid containing the expanded repeat with a gene recognition reagent described in any one of claims 1 to 32.

34. The nucleic acid has (GAA) on both of the two strands. n , (CGG) n , (CCG) n , (CAG) n , (CTG) n , (CCTG) n , (ATTCT) n , or (GGGGCC) n 34. The method of claim 33, comprising a unit target sequence formed by sequential repeats of:

35. The nucleic acid has (CAG) on both of the two strands. n 34. The method of claim 33, comprising a unit target sequence formed by sequential repetition of: or a sequence complementary thereto.

36. 34. The method of claim 33, wherein the nucleic acid is obtained from a patient having a repeat expansion disorder.

37. 33. A method for identifying the presence of a nucleic acid comprising an expanded repeat associated with a repeat expansion disease in a sample obtained from a patient, comprising contacting a nucleic acid sample obtained from the patient with a gene recognition reagent according to any one of claims 2 to 32, determining whether binding and ligation of the gene recognition reagent occurs, indicating that the sample contains a nucleic acid comprising an expanded repeat associated with a repeat expansion disease, and optionally treating the patient for the repeat expansion disease.

38. A composition comprising the gene recognition reagent according to any one of claims 1 to 32 and a pharma- ceutically acceptable carrier.

39. A method for knocking down expression of a gene containing an expanded repeat associated with a repeat expansion disease in a cell, the method comprising contacting a nucleic acid, such as an RNA, that contains the expanded repeat with a gene recognition reagent according to any one of claims 1 to 32.

Citation Information

Patent Citations

  • Gamma-PNA miniprobes for fluorescent labeling

    US20150197793A1

  • Divalent nucleobase compounds and uses therefor

    US20160083434A1